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ABSTRACT

Interaction between positive and negative effectors of embryonic and
postnatal muscle growth in the chicken and the mouse.
Scott Allen Gahr
Myostatin, belonging to the TGF-β family, negatively regulates skeletal muscle
growth. The current study was conducted to assess the efficacy of in ovo administration
of exogenous myostatin antagonist (MA) to enhance skeletal muscle growth and improve
feed efficiency of broilers. Eggs were divided into three groups: uninjected control,
vehicle-injected control and MA injected (600 ng per embryo). Eggs were injected once
on either day 15 or 18 of embryogensis. In ovo administration of MA on day 15 resulted
in the greatest increase in live weights (~8%, P<0.10), breast weights (~14%, P<0.05),
leg weights (~10%, P<0.10) and shank length (~7%, P<0.01) in six-week old female
broilers. Feed efficiency of the day 15 and day 18 MA injected mixed-sex broilers was
unaffected at six weeks of age. Texture analysis showed the MA to have no effect on the
shear force of the pectoralis muscle. Day 15 injected males did not have as pronounced
effect as females in the measured variables. These findings suggest that in ovo
administration of MA may provide a means to improve broiler productivity and
profitability.
Growth hormone secretion is under the control of a pair of hypothalamic factors,
growth hormone releasing hormone and somatostatin. The growth hormone secretagogue
receptor (GHSR) and its endogenous ligand represent a novel third mechanism regulating
the release of growth hormone. Early chicken embryonic development, prior to day 14,
has been proposed to be independent of GH. However, recent evidence shows that
peripheral GH secretion has paracrine/autocrine functions during embryonic
development. In the current study, we used the reverse-transcriptase polymerase chain
reaction to determine the expression pattern of the GHSR during embryonic development
and the effects of in ovo recombinant human (rh) IGF-I administration on its expression
pattern. Eggs were injected once with 100 ng rhIGF-I in 10 mM acetic acid, and 0.1 %
BSA per embryo on embryonic day 3. Total RNA was isolated from whole embryos on
embryonic day E0-6 (n=6 per day), thoracic/abdominal halves of the embryos on E7-E8
(n= 6 per day) and Pectoralis muscle on E9-E20 (n= 4 per day). We found that GHSR
expression was low during E0-E4, followed by an increase on E5 and remained constant
through E17. GHSR expression then increased on E18 before reducing on E20. A
similar pattern was found in the rhIGF-I treated embryos with the exception of a
significant increase in GHSR expression on E8. These data indicate that the GHSR may
be active in regulating GH secretion during early embryonic development, and
upregulation of the GHSR gene following IGF-I administration may have an important
role in the determination of postnatal muscle growth.
Administration of the recently identified ligand of the growth hormone
secretagoue receptor (GHSR) has been found to increase feed intake and fat deposition.
During growth and aging, the myostatin knockout mouse has been shown to have a
significant reduction in fat accumulation. In this study, we used RT-PCR to investigate
the relationship between ghrelin and myostatin expression. Total RNA was isolated from

the brain, heart, pectoralis muscle, kidney and liver of nine-month-old myostatin
knockout (n=3) and control (n=3) mice. Ghrelin expression was significantly reduced in
the heart (P<0.05) and showed a trend for reduced expression in the pectoralis muscle
(P=0.07) in myostatin knockout mice. However, ghrelin expression was not different in
the brain, heart and liver between the control and myostatin knockout mice. These data
indicate loss of myostatin may act by down regulating the expression of ghrelin to reduce
the accumulation of fat in the myostatin knockout mouse. Additionally, these data are
consistent with an autocrine/paracrine role for ghrelin, in the peripheral tissues, in
metabolic regulation and nutrient partitioning.
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INTRODUCTION

From the beginning of embryology with Aristotle, the ability to physically study
the chick embryo has proved a very powerful tool for many areas of embryonic
development. Aristotle observed changes in the developing chicken by removing eggs
from a hen’s clutch during different times of incubation. The use of the chicken embryo
has been indispensable in the establishment of the processes leading to muscle
development. The first description of the primary unit embryo segmentation, the somite,
was given by Marcello Malpighi in 1689, using a primitive microscope to observe
changes in the chick embryos during early embryonic development. Although the
African claw-toed frog (Xenopus laevis) has arguably made the greatest contributions to
our understanding of embryonic development, the contribution of the chicken cannot be
understated. In the mid 19th century, Robert Remark laid the framework for muscle
development when he suggested the process of resegmentation, i.e. formation of several
distinct regions, in the within the chick somite (reviewed by Brand-Saberi and Christ,
2000). Although, as I discuss further below, the chicken has been very important in the
elucidation of vertebrate muscle development, a mistake in 1923 by a Dagsboro,
Deleware hatchery added another reason to study chicken muscle development. In that
year Cecile Steele, mistakenly received 500, rather than 50, replacement hens on her
small farm in Delaware. When the birds became to large for the pens that she had, she
was forced to slaughter the chickens and sell for meat for 62 cents per pound. This was
the beginning of the now multi-billion-dollar broiler industry in America, and the impetus
to study chicken muscle development for the chicken muscle.
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LITERATURE REVIEW
Embryonic Origin of Muscle

The embryonic origin of body muscle cells in vertebrates can be traced back to
the paraxial mesoderm in the primitive streak, which is formed during gasturalization of
the early embryo. These cells undergo epithealization and segmentation to form the
somites, the basic metameric unit of the embryo (reviewed by Keynes and Stern, 1988;
Brand-Saberi and Christ, 2000). Somite segments form in pairs starting at the cranial end
and moving cadually along the neural tube and notochord (reviewed by Christ and
Ordahl, 1995; Brand-Saberi and Christ, 2000; Hirsinger et al., 2000). As the somite
matures, the ventral region progresses through a transition from epithelial to
mesenchymal cells making up the scleotome (Christ et al., 1979). The dorsal region
maintains the epithelial identity forming the dermomyotome giving rise to both muscle
cells and the deep layers of the skin.
Use of the Quail/Chick chimeras has allowed for the determination of myogenic
progenitor cell sources in the somite (Ordahl and LeDourain, 1992; methodology review
Ordahl and Christ, 1998). These studies have identified two distinct myogenic lineages
originating from independent regions of the somite. The medial region of the
dermomyotome contains the first cells to express markers of the myogenic fate, myoD,
desmin and myosin (Williams and Ordahl, 1997). These cells form a layer of
differentiated cells under the medial region of the dermomyotome, the myotome, which
form the muscles of the back (Denetclaw et al., 1997). The muscles of the limbs and the
abdominal cavity originate from cells in the lateral region of the dermomyotome (Ordahl
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and LeDourian, 1992; reviewed by Christ and Ordahl, 1995; Brand-Saberi and Christ,
1999).
In addition to the location of cell origin, the quail/chick chimera experiments have
found that cells in these regions of the early somite are not committed to this particular
destination. That is, rotation (Aoyama and Asamoto, 1988), medial to lateral
transplantation (Ordahl and LeDourain, 1992), or ventral to dorsal transplantation (Christ
et al., 1992) of the early somites resulted in the development of the muscles according to
the recipient location and not the donor location. These studies indicate that the
myogenic cells of the somite interact with the surrounding tissues to determine the fate of
the myogenic cells (reviewed by Brand-Sarbri and Christ, 2000)
Unlike the medial region of the demomyotome, which showed early expression of
muscle specific proteins, the lateral region remained undifferentiated for almost two days
beyond myotome differentiation and migrated out of the somite to form the limb and
body wall muscles (Christ et al., 1977). Migration of the myogenic progenitor cells out
of the lateral dermomyotome begins in the cranial edge of the somite, and eventually
cells move out along the whole length (Jacobs et al., 1979; Jacob et al., 1978). At the
limb buds, these myogenic progenitor cells move out of the somite in an undifferentiated
form and become the ventral and dorsal premuscle masses in the limb buds (Schramm
and Solursh, 1990).
Myogenic cell differentiation can be viewed as a process consisting of three steps
(reviewed by Franzini-Armstrong and Fischman, 1994): 1. DNA synthesis ends (cells
become post-mitotic), 2. cytoplasmic fusion, and 3. initiation the transcription of muscle
specific proteins. This process leads to the development of large post-mitotic
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multinucleated myotubes, with centrally located nuclei. As the expression of the muscle
structural proteins increase, the nuclei take up a peripheral location in the cell, and show
the striated appearance of mature muscle cells. Two distinct lineages of cells are used for
growth of the large muscles, referred to as early (embryonic) and late (fetal) myoblasts
forming the primary and secondary myofibers, respectively (Stockdale, 1990). The cell
lineage can be differentiated by the size of and number of nuclei included in the
myotubes formed in vitro (Seed and Hauschka, 1984), and by the specific myosin types
expressed in vivo (Stockdale, 1990). In the chicken, primary myofibers are formed
between days 3.5 and 6 (Stages 28 to 34, Hamburger and Hamilton, 1951) of chicken
embryonic development (Fredette and Landmesser, 1991). In culture, these myoblasts
differentiate into short myotubes containing a relatively low number of myonuceli (~3040; Seed and Hauschka, 1984). In the limb bud, these smaller myotubes express both fast
and slow type myosin heavy chain isoforms (Miller and Stockdale, 1986). The secondary
myofibers, formed after day 7 (Stage 34), show the highest formation between embryonic
day 7 and 17, when there is a 400-fold increase in the number of myofibers in the breast
(O’Neil, 1987). The secondary myoblasts form much longer myotubes in culture
containing upwards of 100 myonuceli (Seed and Hauschka, 1984). The primary
myotubes are thought to create the scaffold over which the much larger secondary
myotubes can grow and provide the bulk of the fibers in the mature muscle (reviewed by
Hauschka, 1994). A summary of the key events in chicken embryonic development is
given in figure I-1.
Investigation into the regulation of myogenic differentiation in vivo was hastened
with the discovery of a family of basic Helix-Loop-Helix (bHLH) transcription factors
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with the ability to transform fibroblasts in vitro into a myogenic lineage (Chio et al.,
1990; Cserjesi and Olson, 1991; Weintraub et al., 1994). These Myogenic Regulatory
Factors (MRFs) include four proteins MyoD, myf-5, myogenin and MRF-4, which are
expressed at different times during avian muscle development (reviewed by Perry and
Rudnicki, 2000). In the chicken, MyoD is expressed first followed very closely by myf5, causing the cells to withdraw from the cell cycle and begin to express muscle specific
proteins (Pownall and Emerson, 1992). MyoD and/or myf-5 activate the expression of
myogenin and MRF-4, which have been found to function in maturation and maintenance
of muscle cells, respectively (reviewed by Megeney and Rudnicki, 1995). Therefore,
MyoD and myf-5 have been referred to as the myogenic determination factors, and
myogenin and MRF-4 have become know as the maturation factors.
As mentioned above, the initial step in myogenic differentiation is withdrawal
from the cell cycle prior to the expression of the muscle specific proteins and formation
of the myotubes. Therefore, the process of proliferation and differentiation in the muscle
cells are mutually exclusive processes during muscle growth. Interaction of the activities
of proliferative and differentiative factor on the cells determines the number of mature
myofibers in any given muscle. The interaction of growth factors on the maturation of
the myoblasts has been show by the effects of serum concentrations in culture on the
differentiation of myogenic cells. Depletion of the serum from the culture media results
in the cells fusing to form the myotubes and expression of muscle specific proteins
(Konigsberg, 1971). Using serum-free media with varing levels of specific growth
factors has allowed the elucidation of theses growth factors effects on myoblast
proliferation and differentiation (reviewed by Hauschka, 1994). Fibroblast Growth
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Factors (FGF), Insulin-like Growth Factors (IGF) and Transforming Growth Factor-β
(TGF-β) are perhaps the most extensively studied of these growth factors, and represent
the variety of effects growth factors can have on myoblast proliferation and
differentiation (reviewed by Florini and Margi, 1989; Ewton and Florini, 1990; Florini et
al., 1991). FGF is a very potent stimulator of myoblast proliferation and inhibitor of
differentiation. TGF-β is a very potent inhibitor of both myoblast proliferation and
differentiation, and is thought to be the most potent inhibitor of proliferation. IGF-I, and
to a lesser extent IGF-II, have been shown to stimulate both proliferation and
differentiation of myoblasts in a biphasic dosage manner.
Although, tissue culture has proven helpful in the elucidation of the effects of
growth factors on the myogenic differentiation process; however, the effective culture
systems still required the influences of at least minor amounts of unidentified factors,
typically supplied in serum supplements. The identification of additional factors
expressed either within the developing muscles or secreted from surrounding tissues,
such as the bone morphogenic proteins, Pax-3, and sonic hedgehog in the developing
embryo, creates combinations of signals that as of now cannot be accurately replicated in
culture (Amthor et al., 1999; reviewed by Buscher and Belmonte, 1999).
The discussion above indicates the complexity of the generation and maintenance
of normal muscle growth. The interaction between positive and negative growth factors
acts to determine both the number of muscle cells and the size of the fibers. The recently
identified negative regulator of muscle growth, myostatin (also known as
growth/differentiation factor-8) has been found to have a significant role in determination
of the muscle size in mammals (Lee and McPherron, 1997; Bass et al., 1999). However,
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the role of myostatin in regulation of muscle growth and development in the avian
species has not received much attention. In contrast to the negative effects of myostatin,
the somatotrophic axis (Hypothalamusà Pituitary (growth hormone)àIGF) must be
intact to stimulate muscle growth in the avian species. The regulation of GH secretion by
the anterior pituitary in the avian species is regulated by the interaction of secreatory
factors (growth hormone-releasing hormone and thyrotropin-releasing hormone) and
inhibitors (somatostatin) (reviewed by Scanes 1997). An additional mechanism
regulating the secretion of GH has been proposed with the identification of a group of
peptides and non-peptidyl analogues known as the GH secretagogues acting through a
common receptor (the growth hormone secretagogue receptor (GHSR)) (Reviewed by
Smith et al., 1997). For this reason, the biological activities of myostatin (negative
regulator) and the growth hormone secretagogues (positive regulators) have been
reviewed in the following sections.

Myostatin
Beef cattle breeding has extensively selected for increased muscle mass. In
Europe, the breeding regime has lead to the isolation of the ‘double muscle’ phenotype,
which is a heritable trait characterized by a significant increase in the number of muscle
fibers (Casas et al., 1998). An additional mammalian model of this phenotype was
identified in the compact mouse (Varga et al., 1997). The genotype leading to this
phenotype remained unresolved until the identification of a novel member of the
transforming growth factor-β (TGF-β) super family, myostatin (McPherron et al., 1997).
This group found that knocking out this gene resulted in a 200-300% increase in the
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muscling of the mouse. Subsequent analyses have shown the double muscle and compact
phenotypes are related to natural mutations in the myostatin gene. Since its identification
5 years ago, much has been learned about myostatin, however, there are still several
unresolved questions that must be addressed to fully understand the role of myostatin in
the regulation of muscle growth and development.

What is Myostatin?
Se-Jin Lee’s group at John Hopkins University using degenerative PCR to
identify novel members of the TGF-β family, identified a gene that they referred to as
growth/differentiation factor-8 (GDF-8). Using homologous recombination, they
generated a GDF-8 null mutant mouse, which showed a significant increase in muscle
mass (McPherron et al., 1997). This increase in muscle mass was the result of both
increased muscle cell number (hyperplasia) and increased muscle fiber size
(hypertrophy). Therefore, GDF-8’s role as a negative regulator of muscle growth led to
its now common name, myostatin.
To date, more that 30 members of the TGF-β family have been identified.
Members of the family have been found to have roles in the regulation of cell
differentiation, proliferation and lineage determination (reviewed by Massague, 1998).
Structurally, members of the TGF-β family share at least three common features (Figure
I2; reviewed by McPherron and Lee, 1996). Myostatin is translated as a 376-aa protein
showing all three of the hallmarks of other members of the TGF-β family. First, the Nterminus contains a number of hydrophobic amino acids, which function as a signal
sequence for secretion. Myostatin’s first 40 amino acids show a high proportion of
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hydrophobic residues, indicating the presence of this element.

Second, the presence of a

conserved RSRR proteolytic recognition site in the C-terminal domain indicates the
secretion of the protein in an inactive form, which must subsequently undergo proteolytic
cleavage for activation. This sequence is present between amino acids 264-267 in
myostatin. Additionally, western blot analysis of purified myostatin proteins under
reducing conditions shows small (~12.5 kDa) and large (~36 kDa) bands, reflecting the
presence of the propeptide and the activated C-terminal monomer (Lee and McPherron,
2001). The final general characteristic of the TGF-β proteins is the presence of six to
nine cysteine residues in the C-terminus, which are responsible for ‘cysteine knot’
formation during homodimerization; myostatin contains nine cysteines in its C-terminus.
Western analysis of purified myostatin verified the homodimerization with the ~12.5
kDa monomers detected under the reducing conditions and ~25 kDa under the nonreducing conditions (Lee and McPherron, 2001).
TGF-β family members signal through cell surface receptor activation to elicit
their biological responses (Figure I3; reviewed by Massague, 1998). Binding of a
homodimer of the activated C-terminal to the TGF-β type II receptor recruits the type I
receptor to modulate gene expression of the cells. Using radioiodinated myostatin, Lee
and McPherron (2001) found that myostatin also binds to the activin receptor type II.
More specifically, they found that the affinity of myostatin was highest for the activin
receptor type-IIB (ActRIIB). This finding provides further evidence that myostatin is a
member of the TFG-β family (Lee and McPherron, 2001). Additionally, expression of a
dominant negative ActRIIB in the mouse causes phenotypic changes in the mouse similar
to the myostatin knockout mouse, indicating active signaling though this receptor.
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Where is Myostatin Expressed?
As mentioned above, the myostatin null mouse shows a significant increase in
muscle mass (McPherron et al., 1997) indicating a major role in the regulation of muscle
cell proliferation. The 100% conservation of the sequence within the biologically active
C-terminal domain of the human, murine, rat, porcine, chicken, and turkey indicates a
remarkably conservation of function amoung these species (McPherron et al., 1997).
Embryonic expression pattern for myostatin in the mouse (McPherron et al., 1997), cattle
(Kambadur et al., 1997) and chicken (Kocamis et al., 1999b) all reflect the muscle
specific role for myostatin during embryonic development. In the mouse, the initial
expression of myostatin was detected in the myotome region of the somite, moving out
into the limb and body cavity as the myoblasts began to mature (McPherron et al., 1997).
In cattle, Kambadur et al., (1997) found low myostatin expression before day 29 of
gestation, which increased on day 31 and remained high in the developing muscle. This
time period is consistent with the timing of primary myoblast differentiation in the
bovine. Additionally, the dramatic increase in the expression of myostatin on embryonic
days 7 and 17 during chicken development overlaps with the approximate timing of
primary and secondary muscle fiber formation (Figure I1; Kocamis et al., 1999b). They
also observed a reduction in myostatin expression just prior to hatch, when muscle
development is most likely completed.
Post-natally, myostatin expression appears primarily in skeletal muscle
(McPherron et al., 1997; Kambadur et al., 1997). In murine samples, significantly higher
expression has been found in the Planteris and the Gastrocnemius as compared to the
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Soleus (Wehling et al., 2000; Carlson et al., 1999), indicating higher myostatin
expression is associated with fast type muscle fibers. Similarly, in cultured myoblasts,
the expression of myostatin was associated with the myotubes expressing the fast type
myosin heavy chain (Artaza et al., 2002). To further expand the role of myostatin in
muscle growth and development, up regulation of myostatin was reported in conditions
leading to muscle wasting including, limb unloading (Wehling et al., 2000; Carlson et al.,
1999), exposure to zero gravity during space flight (Lalani et al., 2000), extended periods
of bed rest (Reardon et al., 2001), aging (Marcell et al., 2001), and advanced HIV
(Cadavid-Gonzales et al., 1998).
Outside the skeletal muscle, lower levels of myostatin expression has been
reported in adipose tissue (McPherron et al., 1997), Purkinje fibers of the heart (Sharma
et al., 1999) and in the tubuloalveolar secreatory lobules of the lactating mammary gland
of pigs (Ji et al., 1998). The significances of this requires further investigation.

How Does Myostatin Function?
The limited expression of myostatin outside the skeletal muscle indicates
myostatin may be acting in an autocrine/paracrine manner in the regulation of skeletal
muscle proliferation (McPherron et al., 1997). Several studies have shown myostatin to
reduce myoblast proliferation in culture (Thomas et al., 2000; Taylor et al., 2001; Rios et
al., 2001; Artaza et al., 2002) consistent with the loss of active myostatin leading to the
‘double muscle’ phenotype. Actively dividing cells are dependent on the activity of the
cyclins and cyclin-dependant kinases (CDK) for progression through the cell cycle.
Thomas et al. (2000) found upregulation in the transcription of the CDK inhibitor (CDI)
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p21 in C2C12 cells treated with exogenous myostatin. Therefore, attenuation of the CDK
activity clearly leads to withdrawal of the myoblasts from the cell cycle leading to the
anti-proliferative effects of myostatin. Recently, Zimmers et al., (2002) found in vivo
over-expression of myostatin, by the induction of myostatin expressing tumors, that
increased myostatin lead to a cachxia-like phenotype in the mouse. This demonstrates
that myostatin is active in reducing the proliferation of myoblasts in vivo. This also
indicates a systemic effect of myostatin, which is addressed below.
Unlike the clearly defined role of myostatin in myoblast proliferation, the effect
of myostatin on cell differentiation and survival (apoptosis) has not been clearly defined.
Initially, there was shown to be no visible change in myoblast differentiation in vitro with
myostatin treatment (Thomas et al., 2000). However, the effects on muscle
differentiation were shown with the reduced protein synthesis in C2C12 cells treated with
myostatin (Talyor et al., 2001). Additionally, Rios et al., (2002) found that myostatin
decreased expression of markers of muscle cell differentiation, myogenin and creatine
kinase. Similar to the confounding results on myoblast differentiation, the effect of
myostatin on cell survival has not been consistent. Using the TUNEL assay and cell
sorting, Thomas et al. (2000) were unable to show any apoptotic or anti-apoptotic effects
of myostatin. A more recent study showed myostatin was able to reduce to cell death in
the same type of cell culture (Rio et al., 2001). These confounding result are intriguing
and warrant further investigation. Collectively, the data above indicate myostatin acts to
reduce myoblasts proliferation in culture and provide evidence that in vivo loss of active
myostatin leads to increased muscle.
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Generation of a myostatin knockout mouse (McPherron et al., 1997) and
identification of natural mutations in the myostatin gene in mice (Szabo et al., 1998) and
cattle (McPherron and Lee, 1997; Smith et al., 1997; Grobet et al., 1998) show that
myostatin attenuation leads to a ‘double muscle’ phenotype. Therefore, methods to
attenuate myostatin activity in vivo may prove useful in the treatment of muscular
diseases. The activity of TGF-β family members is regulated by proteolytic cleavage,
dimerization and interaction with the receptors (see figure I2). Analysis of the mutation
in the Piedmontese and Belgian Blue cattle indicate that a reduction in myostatin activity
presumably leads to the double muscle phenotype. In the Piedmontese, a 2-bp mutation
in the gene results in the substitution of tyrosine for the cysteine at residue 313. This
presumably acts to prevent ‘cysteine knot’ formation during dimerization, therefore,
attenuating the activity of myostatin (McPherron and Lee, 1997; Kambadur et al., 1997).
Similarly, an 11-bp mutation in the Belgian Blue myostatin gene results in a truncated
myostatin protein. Similarly, the generation of a mouse with an altered proteolytic
cleavage site on myostatin showed a significant increase in muscle mass (Zhu et al.,
2000). Therefore, attenuation of myostatin activity results in an increase in the muscle
mass regardless of the method by which endogenous myostatin activity is blocked.
The binding of the active protein to the cleaved prodomain (also known as
latency-associated protein) or binding proteins (e.g. follistatin, noggin and α-2macroglobulin) may also attenuate TGF-β family member activity (Figure I2; reviewed
by Piek et al., 1999). In receptor binding assays, both follistatin and the N-terminal
propeptide were found to significantly reduce myostatin receptor binding (Lee and
McPherron, 2001). Creation of transgenic mice over expressing either follistatin (Lee

13

and McPherron, 2001) or the prodomain (Yang et al., 2001) under the direction of a
muscle specific promoter, lead to a significant increase in muscle mass. In summary,
attenuation of myostatin activity may be achieved through manipulation of the regulatory
mechanisms controlling activity of myostatin protein. Understanding of these
mechanisms may have important implications in human health and agricultural
production.

Non-muscle Roles of Myostatin?
Generation of the myostatin knockout mouse and identification of the mutation
leading to the ‘double muscle’ phenotype have led to investigations of myostatin that
specifically focus on the paracrine/autocrine effects of myostatin on the growth and
development of muscle (Lee and McPherron, 1999; Bass et al., 1999). However, more
recent data indicate that myostatin may have roles reaching far beyond muscle alone and
may be an actively circulating growth factor. In fish, two different myostatin proteins
have been isolated (Roberts and Geitz, 2001; Rodgers et al., 2001; Rescan et al., 2001)
with expression reported in a variety of tissues outside of muscle. One of the isoforms
was found to be ubiquitously expressed in fish tissues, the other was limited to expression
in the skeletal muscle and brain (Rescan et al., 2001; Ostbyte et al., 2001). This suggests,
at least in the lower vertebrates, a more extensive role for myostatin in growth,
development or other processes.
Nutrient partitioning isof particular interest to the agricultura industry to improve
the value of the product produced. As mentioned earlier, a low level of myostatin
expression was reported in fat tissues of mice (McPherron et al., 1997). However, until
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recently, this expression was considered insignificant. Treatment of 3T3-L1
preadipocytes with myostatin reduced expression of CCAAT/enhancer binding protein
alpha (C/EBP alpha) and peroxisome proliferator-activated receptor gamma (PPAR
gamma), the main proteins involved in adipocyte differentiation (Kim et al., 2001).
Similarly, Lin et al., (2002) found that the regulation of these same genes was altered in
the myostatin null mouse. They concluded that these changes were the cause of the
reduced adipogenesis observed during growth of the mouse. Crossing of the myostatin
knockout mice with either the Agouti lethal (Ay) or the Obese (ob/ob) mice, animal
models of obesity and diabetes, not only resulted in a significant reduction in fat
deposition in the hybrids, but also showed changes in the animal’s glucose tolerance
(McPherron and Lee, 2002). We have recently found IGF-II gene expression was
significantly increased in the kidney and soleus muscle of the myostatin knockout mouse
(Kocamis et al., 2002). This may indicate one mechanism by which metabolism is
altered. That is, IGF-II is able to bind to and activate the insulin receptor, therefore IGFII acting through the insulin receptor may cause, at least in part, the observed changes in
the fat deposition and glucose metabolism (Lin et al., 2002; McPherron and Lee, 2002).
Thus, alterations in fat deposition and metabolism in the mouse resulting form myostatin
attenuation may be the interaction of direct and indirect activities on the fat tissues.
A systemic role of myostatin has been the source of some debate, in part because
the ability to detect myostatin in the circulation has been hindered by the lack of available
antibodies available. In 1998, Cadavid-Gonzales et al., were the first to indicate the
presence of myostatin proteins in the circulation of humans, which were increased during
HIV induced muscle wasting. However, the protein they identified as myostatin was
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~30kDa, much larger than the ~12.5 kDa myostatin monomer and the ~25kDa dimer (Lee
and McPherron, 2001). Using a newly developed antibody specific for the C-terminus of
myostatin, Zimmers et al., (2002) were able to show a measurable amount of the specific
myostatin monomer, at ~12.5 kDa, in the wild-type mouse, a protein not identifiable in
myostatin knockout mouse serum. In the same study, establishment of CHO-myostatin
tumors in the muscles resulted in a cachexia–like response, which was not limited to the
muscle in which the tumors grew further supporting a systemic role for myostatin.
Therefore, myostatin blocking agents, receptor agonists or myostatin binding proteins,
may be effective treatments for muscle wasting conditions in humans.
The presence of the Belgian Blue 11-bp mutation in the South Devon cattle
population, which is not considered as double muscled, indicates that interaction with
other genetic factors (i.e. genetic background) are necessary (Smith et al., 2000).
Additionally, both the Callipyge sheep (Freking et al., 1998) and the Pietrain Pig (Brenig
and Brem, 1992) show increased muscling, but the markers of this type of muscle
hypertrophy have been found in regions of the genome independent of the myostatin
location. This provides evidence that the genetic background of the animal that carries a
mutation in myostatin determines the degree of muscular growth. Some factors that may
be involved in this include genes regulating the proliferation of the muscle cells, i.e. GH,
IGF’s and/or FGF’s or those proteins that interact directly with myostatin or the
components of its signaling pathway (see Figure I3).
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Growth Hormone/IGF-I and Growth
Somatic growth, defined as the increase in body size or weight, is regulated by the
interaction of external (environmental and nutritional) and endogenous (hormonal)
stimuli. A fundamental role for growth hormone (GH; also known as somatotropin) is
well established as a hormonal regulator of postnatal growth. The somatotroph cells of
the anterior pituitary serve as the site of GH production and secretion. In most vertebrate
species, hypophysectomy results in a significant reduction in body weight gain, bone
growth and reduced growth of several organs (reviewed by Scanes et al., 1986), which
can be mostly overcome by supplementation with exogenous GH (reviewed by Butler
and LeRoith, 2001). Similarly, many of the genetic causes of growth retardation in
animals, both mutations and knockouts, are found within the GH system (reviewed by
Sellier, 2000). For example, Laron-Type Dwarfism and the sex linked dwarf (SLD)
chicken have severe growth retardation resulting from a mutation in the GH-receptor
gene (GH-R; reviewed by Hull and Harvey, 1999).
GH, belonging to the large family of cytokine peptides, has been proposed to have
evolved from a common ancestral gene with prolactin and placental lactogen (reviewed
by Miller and Eberhardt, 1983). In the chicken, GH is translated as a 216-aa peptide,
containing a 25-aa signal sequence on the N-terminus, and a 191-aa mature protein,
which shows 79% homology to the rat GH sequence (Lamb et al., 1988). The mature
protein has a molecular weight of approximately 22 kDa and contains two disulfide
linkages, which are proposed to have an important role in determination of its secondary
structure and therefore ligand-receptor interactions (reviewed by Kopchick and Chen,
1999). The effects of GH on the cell are mediated through the transmembrane growth
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hormone receptor (GH-R) by activating the JAK/STAT signal transduction pathway
(reviewed by Carter-Su et al., 1996).
Early studies proposed that GH’s effects on growth were mediated through an
intermediate or a somatomedin to promote growth. This theory had become commonly
referred to as the ‘somatomedin hypothesis’ (Salmon and Daughaday, 1957; reviewed by
LeRoith et al, 2001). The purification of the insulin-like growth factor-I (IGF-I), named
for its ability to stimulate glucose uptake by fat and muscle cells, provided the
intermediate for the mediation of GH effects to the target tissues (Rinderknecht and
Humbel, 1978; Klapper et al., 1983). Not only was IGF-I found to be a potent mitogen,
but its secretion from the liver is regulated by GH. Therefore, the somatomedin
hypothesis stated that GH secretion from the anterior pituitary regulated the secretion of
IGF-I by the liver, mediating the effects to the target tissues (Figure I4; reviewed by
LeRoith et al., 2001). The original somatomedin hypothesis was challenged in the 1980’s
by the discovery of IGF-I expression in extrahepatic tissues, which was regulated by GH
(D’Ercole et al., 1984; Roberts et al., 1987). In 1985, Green et al., reported the effects of
GH and IGF-I on 3T3 pre-adipocytes were exclusive. That is, GH stimulated
differentiation of the pre-adipocytes, whereas IGF-I resulted in the expansion of the cell
populations, a finding that was supported by the effects reported on longitudinal bone
growth and chondrocyte differentiation (reviewed by Isaksson et al., 1987). From this, a
‘dual effector’ theory was proposed to describe the activity of the GH/IGF-I axis on
growth in the animal, which proposed that GH acted directly on the cells to determine the
cellular fate and induced the expression of IGF-I that allowed for the clonal expansion of
the cells. The discovery of expansion of chondrocytes in the IGF-I knockout mouse
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indicates that the effects of GH on longitudinal plate growth are independent of GH
(Wang et al., 1999). Even though this likely disproves the true ‘dual effector’ theory, the
discovery that GH is able to induce IGF-I expression in extrahepatic tissues is very
important in understanding growth regulatory mechanisms of GH in vivo. The evaluation
of the GH/IGF-I axis described above is illustrated in Figure I4.
In most farm animals, exogenous GH has been found to significantly increase
growth rate, improve feed conversion efficiency, increase lean tissue accretion and
decrease fat deposition (reviewed by Etherton and Bouman, 1998).

This is likely a

reflection of the metabolic effects of GH, which is most evident on adipose and muscle
cell metabolism (reviewed by Florini et al., 1996; Butler and LeRoith, 2001). The
reduced adipocyte volume (Lee et al., 1994) and reduced lipid content of the muscle
(Lafaucheur et al., 1992) indicate that chronic GH administration reduces lipid
deposition. In cattle (Peters, 1986) and swine (Wolverton et al., 1992), this response was
proposed to be the result of reduced lipogensis. However, in the chicken, the same effect
appears to be the result of increased lipolysis in the adipose tissues (Vasilatos-Younken et
al., 1988). Additionally, chronic GH administration reduces blood urea nitrogen in cattle
(Eisemann et al., 1986) and pigs (Etherton et al., 1987) indicating a reduction in the total
breakdown of amino acids. GH treatment has been found to increase protein accretion in
cattle hind limb muscle by as much as 53% (Boisclair et al., 1994). Whether these effects
are direct or mediated thought the IGF’s is a matter of some controversy. In the muscle it
appears the increased growth and protein accretion can be largely attributed to the action
of IGF-I, produced both locally and systemically (reviewed by Florini et al., 1996).
However, the expression of the GH-R in the perpherial tissues, allows for some direct

19

action on the cells, even if it is just to increase cellular responsiveness to lipolytic signals
(reviewed by Scanes, 1999).
Unlike the result in large farm animals indicated above, the results of GH
administration to the chicken have not been consistently observed (reviewed by Scanes et
al., 1986; Vasilatos-Youken et al., 1999). This may be the result of the relationship
between GH and thyroid hormone levels in the chicken. The activity of thyroid hormone
in the chicken results from the interaction of activation and inactivation of thyroxine
(T4), the primary form of thyroid hormone secreted by the thyroid gland. The
metabolically active form 3,3’,5,-triiodothyronine (T3), is formed by outer ring
deiodination catalyzed by iodothyronine deiodinase type I and type II primarily in the
liver. The inactivation of T4 to rT3 (or T3 to T2) by the inner ring deiodination is
catalyzed by type I and type III deiodinases (reviewed by Darras et al., 2000). The SLD
chicken is characterized by high GH and low IGF-I serum concentrations, show a
significant reduction in circulating concentrations of GH following T4 treatment (TixierBoichard et al., 1990).

Also, in a hypothyroid state, the elevated GH concentrations

observed were not matched by increases in the circulating levels of IGF-I (Decuypere et
al., 1987). Additionally, the same study found administration of T3 resulted in a
reduction in GH concentration without further lowering the IGF-I concentration. These
data suggests that the concentration of the thyroid hormones may alter the liver
sensitivity to GH and thereby alter the secretion of IGF-I (reviewed by VasilatosYounken et al., 1999). Therefore the interaction between GH and the thyroid hormones
has been proposed to have a major effect on the growth of poultry.
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In addition to the effects of thyroid hormone on the GH related effects on growth,
GH may also be acting to regulate the levels of thyroid hormone, having significant
consequences on the metabolic regulation of the birds. A significant effect of GH on the
levles of the individual forms of the thyroid hormones has been demonstrated using both
exogenously supplied GH (Vasilatos-Younken et al. 2000) and in a natural model (the
naked neck chicken, Gonzales et al., 1999). The pulsatile infusion of cGH (100 µg/kg
body weight) resulted in a significant increase in the serum T3 without altering T4
(Vasilatos-Younken et al., 2000). They found a significant reduction in the hepatic Type
III deiododinase activity in response to the GH infuson, which explains the increase in
circulating T3 concentrations in the birds. Additionally, the naked neck chicken,
characterized as having lower feed conversion efficiency and much slower growth rate
than the commercially available broiler strains (Gonzales et al., 1998), was shown to have
higher GH concentration during the rapidly growing period (hatch through week 7;
Gonzales et al., 1999). These chickens had higher serum T3 and T3/T4 ratio during this
same period. The induction of a hyperthyroid (high T3/T4 ratio) state resulted in a
decline in the cirulationg IGF-I concentration (Goddard et al., 1988). Taken together,
these data demonstrate that the hyperthyroid state of chickens with elevated GH may
attenuate the effects of GH on whole animal and muscle growth.
The comparatively late development of the anterior pituitary suggests that much
of embryonic development occurs independent of growth hormone. In the chicken, the
exact timing of somatotroph differentiation is a source of some debate. The first
detectible GH secreting cells in the anterior pituitary have been found at two different
times E4.5 (Thommes et al., 1987) or E12 (Jozsa et al., 1979, Malamed et al., 1993).
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However, using the reverse hemolytic plaque assay, Porter et al. (1995) determined that
GH secretion in somatotroph cells was limited before E12. Similarly, the ability of GH
releasing hormone to induce GH secretion during embryonic development was
significantly limited before E14 (Darras et al., 1994). The lack of detectable serum
growth hormone until embryonic day 17 (E17) (Harvey et al., 1979) and pituitary GH
mRNA until E18 (McCann-Levorse et al., 1992) has lead to the conclusion that early
embryonic chicken development is GH-independent.
However, Harvey et al. (2000) found GH-immunoreactivity and GH Receptor
(GHR)-immunoreactivity throughout the peripheral tissues of E3, E6 and E7 chick
embryos. Additionally, mRNA expression of GH from whole embryo was detected
during this time period, well before differentiation of the somatotroph (E16, Porter et al.,
1995), suggesting an anterior pituitary-independent role for GH during early embryonic
development (Harvey et al., 2000, Murphy and Harvey, 2001). Expression of the GH
regulated gene-1 (GHRG-1) in many, but not all, tissues on E8 shows active signalling
through the GH-R during embryonic development, supporting an autocrine/paracrine
pattern of signalling during early embryonic development (Harvey et al., 2001).
Therefore, modulation of GH synthesis during early embryonic development may
provide a method to alter postnatal growth.
The pulsatile release of GH is regulated by the complex interaction of stimulatory
and inhibitory factors acting on the somatotroph cells of the anterior pituitary (Figure I5;
reviewed by Muller et al, 1999). In all vertebrate species studies, the primary control of
GH secretion is regulated by a pair of hypothalamic factors, the GH-releasing hormone
(GHRH; stimulatory) and somatostatin (SS; inhibitory). In the chicken, in addition to
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GHRH, an additional hypothalamic stimulatory factor has been identified thyrotropinreleasing hormone (TRH; reviewed by Scanes et al., 1984). In addition to these local
signals, both GH and IGF-I have been found to inhibit the secretion of GH through
inhibition of GHRH in the hypothalamus and directly on the somatotroph cells of the
anterior pituitary (reviewed by Muller et al., 1999). In the chicken, as opposed to
mammals, thyroid hormones, particularly T3, have been shown to be a potent inhibitors
of GH secretion (reviewed by Scanes et al., 1984). This effect is particularly evident in
the SLD chicken, in which the high concentrations of GH in the animal are returned to
approximately the same level as the normal chicken with exogenous T3 in the feed
(Harvey, 1983). The complex regulation of the secretion of GH represents the interaction
between a variety of factors some which have yet to be identified.

What are the Growth Hormone Secretagogues (GHS)?
In the late 1970’s a group at Tulane University lead by Cyril Bowers were
investigating the opiate potential of Met5-enkephalin derivatives and found them to have
very low or no opiate potential. However, they found that these peptides had the ability
to induce growth hormone secretion from the pituitary (Bowers et al., 1980). Therefore,
they were referred to as the GH releasing peptides (GHRP). Starting with Met5enkephalin (Tyr-Gly-Gly-Phe-Met-NH2) and Leu5-enkephalin (Tyr-Gly-Gly-Phe-LeuNH2), this group investigated the secretory potential of a wide variety of sequence and
structurally related synthetic peptides (Momany et al., 1981; 1984). Several of these
analogues were shown to induce GH secretion in perfused pituitary cell culture, but were
not able to increase serum GH concentrations in vivo. The use of conformation energy
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calculations and nuclear magnetic resonance allowed the identification of the structural
components of the peptide and significantly advanced the rate of discovery of more
potent peptides (Momany et al., 1984). These methodologies lead to the identification of
a hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2; also known as GHRP-6) with the
ability to specifically cause GH release both in vitro and in vivo (Bowers et al., 1984).
Over the next 15 years, a wide variety of peptides were identified with increasing
potencies to increase circulating growth hormone (Figure I6; reviewed by Smith et al.,
1997). In addition to GHRP-6, three additional peptides GHRP-1 (Ala-His-D-β-Nal-AlaTrp-D-Phe-Lys-NH2), GHRP-2 (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2), and Hexarelin
(His-D-2-MeTrp-Ala-Trp-Phe-Lys-NH2) induce GH secretion in a very potent manner
(reviewed by Smith et al., 1997; Bowers et al., 1999).
Although the GHRPs functioned very well to induce the secretion of GH, their
functionality was significantly limited because of low oral bioavailability. Therefore,
two drug companies, Merck and Genentech, used the structural information available to
formulate compounds that could mimic GHRP. Collectively, these peptides and
analogue have become referred as the Growth Hormone Secretagogues (GHS). Three
classes of these non-peptidyl GHSs have been identified based on the internal structural
bases (Figure I7). The benzolactams (Merck drug L-692,429) and the spiroindanes
(Merck drug MK-0677) were based on the central structure of GHRP-6 (reviewed by
Smith et al., 1997). On the other hand, Genentech used the core of GHRP-2 to design the
isonipecotic GHSs (Genentech drugs G-7302 and G-7039; Elias et al., 1995). Each
compound functions through a mechanism distinct from that of the GHRH and therefore
is thought to act through a GHS receptor (see below). The discovery of these non-
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peptidyl forms of the GHS allowed for an orally available form of the GHS, but had not
really increased the understanding of the mechanism by which GH secretion was
induced.

How do the GHS Function?
The GH secratory activity of the GHS had been identified before the identification
of the endogenous GHRH, and for this reason the action of the GHS was believed to act
through the yet to be identified GHRH mechanism (Smith et al., 1980). However, the
almost simultaneous identification of a 40-aa (Rivier et al., 1982) and a 44-aa (Guillemin
et al., 1982) proteins secreted from pancreatic tumors of patients with acromegaly lead to
the identification of the endogenous GHRH (known at the time as GH releasing factor) in
the hypothalamus. However, treatment of pituitary cells with the GHRH agonist did not
attenuate the ability of GHRP-6 (Cheng et al., 1989), Hexarelin (Bowers et al., 1991) or
MK-0677 (Patchett et al., 1995) to induce GH secretion. Additionally, cells treated with
GHRH alone, resulted in an increase in intracellular cAMP levels, a result that was not
reflected in the cellular treatment with either GHRP-6 (Cheng et al., 1989) or MK-0677
(Patchett et al., 1995). These data suggested that the GHS and GHRH were acting via
different mechanisms to induce the release of GH. Alternatively, the GHS may act in the
pituitary or hypothalamus to reduce the sensitivity to or secretion of SS. This possibility
was eliminated by the demonstration that rats passively immunized against SS show
elevated serum GH concentrations with the administration of GHRP-6 or Hexarelin
(Conley et al., 1995). In the same study, they had shown the GHS acted to increase
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intracellular Ca++ concentration, a result not mimiced by treatment with GHRH. Thus, the
activity of the GHS was suggested to act via their own receptor (Figure I8).
Using radiolabeled [35S]MK-0677, Pong et al. (1996) identified a specific fraction
of porcine and rat pituitary membranes with that bound this GHS. Additionally, they
found this binding was not displaced with addition of excess unlabeled GHRH, but was
displaced by GHRP-6 and Hexarelin. Therefore, the existence of a specific GHS receptor
(GHSR) with overlapping affinity was proposed. This receptor was identified by Howard
et al., (1996) using a reverse pharmacological technique. They injected poly-A RNA
from porcine pituitaries into Xenopus oocytes and monitored changes in the intracellular
Ca++ concentrations following MK-0677 treatment to identify cells containing the mRNA
encoding the GHSR. From this, they were able to identify the porcine GHSR, which
encoded a 366 aa protein, containing sequence consistent with the G-protein coupled
seven transmembrane domain (7-TMD) receptor. In addition to the full-length receptor,
termed GHSR 1a, a truncated mRNA was identified encoding a 253-aa protein containing
the first 5-TMDs. Similar to the membrane-binding assay of Pong et al., (1996), this
study found an inability of GHRH to displace labeled MK-0677 from COS-7 cells
expressing this receptor. Additonally, both GHRP-2 and GHRP-6 were shown to
displace MK-0677 from these cells, indicating this is also the same receptor utilized by
the peptide GHS. Based on the homology, this protein was classified into the neurotensin
family of receptors (53-58% homology). The ligand binding domain of the GHSR is
highly conserved, showing a 58% homology between the human and the puffer fish
(Spheroides nephelus), which are separated by more than 400 million years evolutionarily
(Palyha et al., 2000). They also suggested a functional conservation by the binding of the
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GHS to the receptor in both species. Subsequently, three other receptors (GPR38,
GPR39 and FM-3) have been identified showing homology only to the GHSR (McKee et
al., 1997), indicating the potential for more than one receptor with the ability to bind the
GHS.
Identification of the specific GHSR allowed for clarification of the differences
between the GHSR and the GHRH receptor (GHRHR) in the pituitary (Figure I8). That
is, each of these GH releasing stimulators were found to signal through 7-TMD receptors
using a Trimeric G-Protein mechamnism, however their methods of signal transduction
were different. The GHRH utilized the αs subunit of the G-protein to activate adenylyl
cyclase and cAMP synthesis as the 2nd messenger system to stimulate GH secretion.
Alternatively, the GHSR utilizes the α11 and the βγ subunits to activate phospholipase-Cβ
and IP3 to increase intracellular Ca++ concentrations resulting in the secretion of GH
(reviewed by Smith et al., 1997). The existence of this orphan receptor with a unique
signal transduction pathway lead to the proposal of an endogenous ligand that acts in an
independent manner to regulate GH secretion and the identification of the related receptor
lead to the possibility of other roles.
Expression data for the GHSR has been inconsistent, which may be attributed to
the low expression of the receptor even in presumptive target tissues (pituitary and
hypothalamus; reviewed by Howard et al., 2000). However, there is clear evidence
showing the expression of this receptor in the pituitary and several hypothalamic nuclei,
including nuclei not involved in the regulation of GH secretion (Guan et al., 1997). In
this same study using the ribonuclease protection assay, they were unable to identify
expression in peripheral tissues, with the exception of a weak, but consistent signal from
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the pancreas. Using real-time PCR, Gnanapavan et al., (2002) found human GHSR 1a
expression primarily in the pituitary, with lower expression in the thyroid, pancreas,
spleen, myocardium and adrenal gland. However, they found the expression of the
presumed non-functional GHSR 1b in most of the tissues sampled. Papotti et al. (2000)
found Hexarelin binding to receptors in a variety of tissues, with the highest binding
found in the heart and not the brain. Taken together, these data suggest that the active
GHSR may not be the only protein actively binding the GHS, and the subsequent
identification of the other receptors may elucidate some of the non-GH related activities
of the GHS (see below).
Investigations into the effects of the GHS in chicken growth and development
have been significantly limited, however, there is data to support the existence of a
GHSR system in avians. Bowers et al., (1984) showed that GHRP-6 was effective in
stimulating GH secretion in the chicken following pretreatment with excess SS.
However, this response was much lower than similarly treated mammals. A more recent
study, using the more potent non-peptidyl GHS (Merck’s L-692,429), found increased
GH secretion both directly at the anterior pituitary and through stimulation of TRH
secretion from the hypothalamus (Geris et al., 2001). Additionally, Toogood et al. (1999)
identified a cDNA sequence with significant homology to the human GHSR from a
chicken pituitary cDNA library. Together, these data indicate the presence of the GHSR
in the pituitary of the chicken acting to increase the quantity of GH released.
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What is the Endogenous GHS?
Two groups almost simultaneously reported the same gene product as being
different proteins with completely different suggested roles. Tomasetto et al., (2000) in
searching for new gastric proteins to study the function and differentiation of the
stomach, stumbled upon the endogenous ligand of the GHSR. Using cDNA library
screening techniques, this group identified a cDNA encoding a 117-aa propeptide that
showed significant homology to motilin, a regulator of gastric motility. This novel
protein, designated motilin-related peptide, was found to be primarily expressed in the
endocrine cells of the stomach. They proposed a role for this peptide in the regulation of
gastric motility and secretion.
Meanwhile, a Japanese group set out to identify the endougenous ligand for the
GHSR (Kojima et al., 1999; reviewed by Kojima et al., 2001; Pombo et al., 2001). Using
a CHO cell line transfected to express an active GHSR, they screened the ability of
protein extracts from a variety of tissues to activate the GHSR by monitoring changes in
the intracellular Ca++ concentration. Much to their surprise, brain extracts, even when
applied to the cells in high concentrations, were unable to significantly alter intracellular
Ca++ conentrations, but only 1 mg of stomach proteins was required to elicit a significant
response. Using RP-HPLC, the specific protein binding to the GHSR was purified. The
sequence of this 28-aa peptide contained an unidentifiable residue in position 3.
Complementary DNA analysis suggested this amino acid was a serine residue, however,
the construction of a synthetic peptide with a serine residue at position 3 was unable to
bind to the receptor. Additionally, this peptide was 126 mass units smaller than the
purified form of the peptide. After attempting a variety of modifications, they found that
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the addition of an octanoylate residue, an 8-C fatty acid, residue allowed for proper
binding to the receptor and the correct MW of the protein. This protein was called
ghrelin, from ‘ghre’ the Proto-Indo-European root of the word ‘grow’. Nucleic and
amino acid analysis showed that the motilin-related peptide of Tomasetto et al., (2000)
and preproghrelin of Kojima et al., (1999) were exactly the same protein (Figure I9
commented on by Del Rincon et al., 2001). The protein is translated as a 117-aa
prepropeptide and presumably transported to the golgi apparatus for proteolytic
modification and addition of the octanoylate residue to the ser-3 to form the active 28-aa
peptide for secretion. Ghrelin represents the first protein identified to contain a medium
chain fatty acid modification (Kojima et al., 1999). This is speculated to allow peripheral
ghrelin to cross the blood/brain barrier in order to access the pituitary and hypothalamus.
Additonally, this is thought to provide receptor specificity and allow for receptor binding
(discussed further below).
Subsequent analysis of protein samples from the stomach led to the identification
of an alternative form of ghrelin, differing from ghrelin only in the exclusion of the
glutamine residue at amino acid 14 and therefore termed des-Gln14 ghrelin (Hosoda et al.,
2000a). Using Southern Blot and genomic sequence analysis, they determined that this
was the result of splice variation and not a closely related gene. Another ghrelin gene
derived transcript (GGDT) has been identified in the testis of the mouse (Tanaka et al.,
2001). This 320-bp transcript contains a unique 68-bp 5’ sequence and a 252-bp 3’
sequence identical to the ghrelin cDNA. The protein translated from this transcript and
the function of this peptide has yet to be elucidated.
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Using Northern Blot and in situ hybridization, Kojima et al., (1999) found ghrelin
expression was limited to the endocrine cells of the stomach and the arcuate nuclei of the
hypothalamus. However, subsequent studies using much more sensitive reverse
transcription PCR were able to identify ghrelin expression in a variety of peripheral
tissues, including pituitary, kidney, heart, skeletal muscle, liver, spleen and adrenals
(Date et al., 2000; Mori et al., 2000; Gnanapavan et al., 2002). In all of these studies the
highest expression of ghrelin was found in the stomach, and the upper gastrointestinal
tract organs. Additionally, ghrelin expression in the placental tissues has led to the
proposal of a role for ghrelin during embryonic development (Gualillo et al., 2001).

What are the In Vivo Functions of Ghrelin and the GHSs?
In vitro studies (Kojima et al., 1999, Hosoda et al., 2000) and in vivo in rats
(Seoane et al., 2000, Wren et al., 2000, Date et al., 2000) and in humans (Arvat et al.,
2000, Takaya et al., 2000, Peino et al., 2000) showed that exogenously supplied ghrelin
caused GH release. Ghrelin, as with the synthetic GHS, was found to affect GH release
in humans in a dose dependent manner with the GH level returning to pretreatment levels
about 1 hr after a single injection treatment (Seoane et al., 2000, Peino et al., 2000). Both
ghrelin and des-Gln14 ghrelin showed similar abilities to stimulate GH release (Hosoda et
al., 2000). However, removal of the octanoylate group on Ser-3 abolished GH secretion
in vitro and in vivo (Bednarek et al., 2000).
The increase in serum growth hormone concentration is transient in nature after
treatment with either GHS (reviewed by Bowers, 1999) or ghrelin (reviewed by Kojima
et al., 2000). In addition to degradation of the ligand itself, this response has been
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proposed to be the result of modulation of the entire GH/IGF-I axis, in which feedback
results in attenuation of the response (see above). Further support for this mechanism
attenuating the pituitary responsiveness to these GHSs is the down regulation of GHSR
expression in the rat pituitary following administration of bovine GH (Bennett et al.,
1997). Therefore, it may be concluded that administration of a GHS would not interfere
with the normal pulsatility of GH secretion from the pituitary.
It appears that the response of the animal to GHS administration would be to
stimulate the GH/IGF-I axis, which as described above, should translate into an increase
in somatic growth. In fact, exogenously supplied GHS or ghrelin were found to
significantly increase weight gain in humans, mice, rats and pigs (Bowers et al., 1984;
McDowell et al., 1995; Phung et al., 2000; Tschop et al., 2000). The identification of
increased circulating IGF-I concentrations in chronically treated animals, lead to the
conclusion that this was the result of activation of the GH/IGF-I axis in the animals
(Hickey et al., 1997; Svensson et al., 1998). Additionally, the improved feed conversion
efficiency of treated swine, further indicated the effects were mediated in a GH
dependent manner (Phung et al., 2000).
The conclusion that the effects were GH-dependent has been challenged by recent
findings with ghrelin (Tschop et al., 2000; Wren et al., 2000) and to a lesser extent the
GHRP-6 (Lall et al., 2001). Tschop et al., (2000) found that a single injection of ghrelin
peripherally resulted in a significant shift in the metabolism of mice. They found that
ghrelin caused a significant increase in the respiratory quotient, suggesting an increase in
carbohydrate utilization and sparing of fat stores. This is in opposition to reported
lipolytic effects of GH administration (reviewed by Etherton and Bouman, 1998). In fact,
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exogenous ghrelin has been found to increase the fat mass of mice without altering lean
or bone mass (Tschop et al., 2000). Although no studies have demonstrated the same
effects with the syntheic GHS treatment, treatment of obese individuals with synthetic
GHS suggest a similar mechanism of action. In obese individuals treated with MK-0677
for two months, there was an increase in lean body mass, but this was not matched with a
change in fat tissue (Svensson et al., 1998). They suggested that lean mass accretion
could be attributed to the GH response of the GHS, however this would also predict
increased lipolysis, which was not observed in that study. This indicates, that in these
obese individuals, the regulation of fat deposition by the GHS is independent of GH. The
increased fat deposition following ghrelin administration may indicate a role for ghrelin
and the GHS in the development of obesity in humans. However, both obese Caucasian
and Pima Indians show reduced circulating ghrelin concentrations as compared to lean
individuals of the same race (Tschop et al., 2001; English et al., 2002).
The reduced ghrelin concentration in the obese individuals was proposed to be the
result of the perpetual positive energy balance, suggesting a role for ghrelin and GHS in
the regulation of energy balance and feed intake. Exogenous ghrelin and GHRP-2 were
found to significantly increase feed intake in mice and rats (Wren et al., 2001a; Tschop et
al., 2002). Consistent with the role as an appetite-regulating factor, Cummings et al.
(2001) found that ghrelin concentrations rise just prior to meal initiation in humans.
Additionally, increased circulating ghrelin concentrations were observed in dieting obese
individuals (Cummings et al., 2002). Evidence indicates that either ghrelin or GHS are
able to activate the neuropeptide Y (NPY) and agouti-regulated peptide (AGRP)
containing neurons of the hypothalamus (Dickson and Luckman, 1997; Kamegai et al.,
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2001; Tschop et al., 2002). These data indicate that secretion of ghrelin by the stomach is
acting in the hypothalamus as a long-term regulator of feed intake and nutrient
partitioning. This is supported by the significant reduction in circulating ghrelin
concentrations following gastric bypass (Cumming et al., 2002). In contrast to mammals,
intracerebroventricular (ICV) injection of ghrelin into chickens caused a reduction in feed
intake (Furuse et al., 2001). However, in this study, both the type (rat) and the mass
(microgram quantities) of ghrelin may have resulted in abnormal findings. Further
investigation is required to elucidate the mechanism of action of the GHS and ghrelin in
the chicken.
Further implications for GHS in human health are suggested by their involvment
in cancer development and cardiovascular health. The expression of the GHSR in
pituitary adenomas (Korbonits et al., 1998; Kim et al., 2001), breast cancer (Cassoni et
al., 2001), lung carcinoma (Ghe et al., 2002) and prostate cancer (Jeffery et al., 2002) cell
lines suggest a role for GHS in the regulation of growth and development of cancerous
tissue. Treatment of both hepatoma (Murata et al., 2002) and lung carcinoma cells (Ghe
et al., 2002) with GHS and ghrelin increased proliferation of these tumor cells. The
expression of ghrelin along with its receptor in the cancer cells indicates a potential
autocrine/paracrine role for ghrelin in the growth of tumors in vivo (Jeffery et al., 2002).
Expression of the GHSR (Bodart et al., 1999) and GHS binding in myocardial
tissues (Papotti et al., 2000) indicates a role for the GHS and ghrelin in the growth and
development of cardiac function. The effects of the GHS on cardiac function have been
shown both in vitro and in vivo. Locatelli et al., (1999) found that Hexarelin pretreatment
counteracts ischemic damage in perfused rat hearts. This effect was demonstrated in both
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intact and hypophysectomized animals, indicating that the effects were independent of
GH. Additionally, in the pacing induced chronic heart failure model, GHS treatment
improved ventricular function and myocyte contractile properties (King et al., 2000).
Recently, chronic ghrelin treatment was found to improve the hemodynamic parameters,
such as reducing the cardiac afterload and increasing cardiac output without altering heart
rate (Nagaya et al., 2001).
Investigations into the effects of the GHS and ghrelin in the chicken have been
very limited to date. However, identification of the GHSR cDNA sequence (Toogood et
al., 1999) and identification of the GH releasing potential of the GHS (Geris et al., 2001)
in the chicken have provided evidence of an active mechanism. To date, the endogenous
ligand, ghrelin, has yet to be identified in the avian species. However, the identification
of ghrelin immunoreactivity in the chicken pituitary indicates the presence of the ghrelinlike peptide in the chicken (Ahmed and Harvey, 2002). However, this study used a
polyclonal anti-rat ghrelin antibody, and therefore did not conclusively show that the
immunoreactivity was not simply the interaction with a separate octanyolated protein.
Identification of the genomic or mRNA sequence of the ghrelin-like peptide will support
an intact ghrelin-GHSR mechanism in the chicken.
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Figure I1 – Key Events of Embryonic Development

36

Signal Peptide

Prodomain

Mature Peptide

Dimerization

‘RSRR’ Recognition Site
S S S S S
| | | |
S S S S S

‘Cystine Knot’

Proteolytic Cleavage and
Association With Follistatin

Proteolytic Cleavage and
Association With Prodomain

S S S S S
| | | |
S S S S S

S S S S S
| | | |
S S S S S
Dissociation of
Binding Protein

S S S S S
| | | |
S S S S S

Receptor Binding and Signal Transduction

Figure I2 – Activation and Regulation of TGF-β (i.e. myostatin) Family Members.
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Figure I3 – TGF-β Signaling (Adapted from Massague, 1998)
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Figure I4 – A) Evolution of understanding of the GH/IGF-I Axis (from Le Roith et al.,
2001) B) Diagram of the GH/IGF-I in Avians (A/P=Autocrine/Paracrine, ALS/BP3=
Acid-Labile Subunit/Binding Protein 3) from Scanes, 1997).

39

Hypothalamus

Ghrelin

Somatostatin

GHRH
Pituitary

Stomach & Other Tissues

Growth Hormone

Liver & Other Tissues

Stimulatory

IGF-I

Figure I5 – Regulation of Growth Hormone Secretion
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Inhibitory

Figure I6 – Development of the Peptide and non-peptide Growth Hormone Secretagogues
(from Muller et al., 1999)
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Figure I7 – Representative Structure of each class of non-peptidyl Growth Hormone Secretagogue (adapted
from Smith et al., 1997).
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Figure I8 – Divergence of Signal Transduction by the Growth Hormone Releasing
Hormone (GHRH) and the Growth Hormone Secretagogue (MK-0677). (From Smith
et al., 1997)

Des-Gln14-Ghrelin (Human)

Figure I9 – Amino Acid Sequence of Human Ghrelin and des-Gln14-Ghrelin showing the
Location of the Octanoylate Residue on Amino Acid Three.
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Chapter 1
In Ovo Administration Of Myostatin Antagonist Alters Postnatal Growth
And Development Of The Broiler Chicken
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INTRODUCTION

Myostatin (also known as Growth/Differentiation Factor 8), a member of the
Transforming Growth Factor-β (TGF-β) family, is a negative regulator of skeletal muscle
growth (Lee and McPherron, 1999). Targeted disruption of the myostatin gene in the
mouse results in a 200-300% increase in muscle mass compared to that of normal
littermates (McPherron, et al., 1997). In addition, the ‘double muscle’ phenotype in the
Piedmontese and Belgian Blue breeds of cattle are associated with alterations in the
myostatin gene (McPherron and Lee, 1997, Kambadur et al., 1997). Attenuation of the
myostatin gene results in both hyperplasia and hypertrophy of muscle fibers (McPherron
et al., 1997).
As with other members of the TGF-β family, myostatin is translated in a
propeptide form, in which the cleavage of the N-terminus leads to the biologically active
form of these growth factors (Sharma et al., 1999). The biologically active domain, the
carboxyl terminal region, is highly conserved among mammalian and avian species
suggesting a conserved function among these species (McPherron and Lee, 1997). Lee
and McPherron (2001) have shown the ability of the C-terminal region to form dimers,
which in turn bind to the activin type II receptors. This binding is inhibited by the action
of the activin binding protein, follistatin, and to a lesser extent by the propeptide form of
myostatin. Activation of myostatin begins with the removal of the N-terminus, i.e. the
pro domain, which is able to bind to the C-terminal to inactivate myostatin signaling
(reviewed by Sharma et al., 2001). Transgenic mice over expressing the pro domain of
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myostatin show a significant increase in muscle hypertrophy, as a result of attenuated
myostatin signalling (Yang et al., 2001).
In chicken embryonic development, primary muscle fiber formation occurs on
embryonic day 7 and secondary muscle fiber formation occurs between embryonic days 7
and 18 (Feredette and Landmesser, 1991). Kocamis et al. (1999) found that myostatin
expression during chick embryonic development increased on embryonic day 7 in the
thoracic half and on embryonic day 17 in the pectoralis muscle, approximately
overlapping with the timing of muscle fiber formation events. Additionally, they
demonstrated a reduction in expression just prior to hatch when muscle fiber formation is
nearly complete.
At present, ~80% of the broiler industry in America has begun to use in ovo
vaccination against Marek’s disease (Ricks et al., 1999). Therefore, the timing of
vaccination provides an avenue for treatment with growth factors to increase poultry
production. Previous work in our lab has shown that in ovo administration of growth
factors is an effective method to modulate broiler growth and development (Kocamis et
al., 1998). In the current study, we are evaluating the effect of in ovo administration of a
myostatin antagonist (MA) on post hatch muscle growth and feed conversion efficency in
the broiler. We hypothesize that the in ovo attenuation of myostatin will increase muscle
growth without increasing the feed requirement for the additional muscle growth.
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MATERIAL AND METHODS
Experimental Groups
Fertilized eggs (Ross x Ross) were obtained from Rocco Enterprises
(Harrisonburg, VA) and placed into a Buckeye incubator/hatcher (temperature 37 ± .5 C,
humidity 86 to 87%). Preliminary studies were conducted to determine both the optimum
dosage and timing of administration of the myostatin antagonist. The results of these
studies showed that 600 ng of myostatin antagonist administered between Days 15 and 20
of embryonic development showed the maximal response in terms of postnatal broiler
growth. Thus, we selected Day 15 and Day 18 of embryonic development as treatment
days. Eggs were injected once with 100 µL of vehicle (10 mM Acetic Acid, 0.1% BSA)
or 100 µL of vehicle containing 600 ng of myostatin antagonist (MA) (Metamorphix,
Inc., Baltimore, Md). The single injection was administered on either Day 15 or Day 18
of incubation. In addition to the vehicle injected control groups, an uninjected control
group was kept to assess the effect of the in ovo injection procedure. The injection
procedure has been previously described (Kocamis et al., 1998). Briefly, eggs were
removed from the incubator, and the blunt end was sterilized with 70% ethanol. A dental
drill bit was used to make a hole through the shell, without penetrating the chorioallantonic membrane. A 22-gauge needle was used to puncture the membrane and
deliver the 100 µL of vehicle or vehicle containing 600 ng of MA. The hole was sealed
with an adhesive sticker before replacing in the incubator. A total of 1078 eggs were set
in the incubator and assigned to the following groups: uninjected control (226 eggs), Day
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15 Vehicle Injected (213 eggs), Day 15 MA Injected (213 eggs), Day 18 Vehicle Injected
(213 eggs) and Day 18 MA Injected (213 eggs).
At hatch, the birds were vaccinated for Marek’s Disease (200 µL s.c., Murray
McMurray Hatchery, Des Moines, IA) and separated by feather sexing. Four replicates
(pens) of each of the five treatments (Two MA Treated, Two control treated, one
uninjected control) were randomly assigned to a total of 20 pens. In each pen, a total of
48 birds (24 male +24 female) were assigned.

Housing and Data Collection
The animals were housed in open floor pens in a temperature controlled building
with a 24-hr lighting regime. For the first three weeks, the birds were fed a standard
starter ration consisting of 21.2% crude protein and 3080 kcal/kg. Starting at three
weeks, this was replaced by the grower ration consisting of 19.5% crude protein and 3124
kcal/kg. Throughout the study, the birds were given ad libitum access to feed and water.
To assess the effects on growth, pen weights were recorded on a weekly basis up to six
weeks of age. Additionally, the feed was weighed in and the orts determined once a
week to measure feed intake and feed conversion efficiency.
At six weeks of age, 120 birds (12 males and 12 females per treatment) were
randomly selected for analysis of muscle growth and quality. For each bird, the live
weight was recorded, then they were slaughtered and sectioned to determine the whole
breast (muscle + rib cage), leg and thigh, heart, and liver weights. The shank length was
determined using calipers to measure along the medial side of the tibia. From each
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treatment group, Pectoralis major muscles (6 male and 6 female) were collected, vacuum
packed and stored at –20ºC for shear force analysis.
Shear force analysis was conducted as previously outlined (Iqbal et al., 1999).
Briefly, the Pectoralis major muscles were thawed overnight at 4ºC, weighed, then
cooked to an internal temperature of 70ºC on a Farberware Smokeless Indoor Grill
(Farberware, Inc., Bronx, NY). The cooked muscle was cooled to room temperature, and
three to four 1.27-cm diameter cores were made through the thickest portion of the
muscle perpendicular to the fiber orientation. Warner-Bratzler shear value was
determined using an Instron Universal Mechanical Testing Machine (Model TM, Instron
Corp., Canton, MA). A Warner-Bratzler appratus was attached and output was aquired
with a DT 2805 data acquisition board (Data Translation, Marlboro, MA). The data was
processed with the HP-VEE software package (Hewlett Packard Co., Loveland, CO).

Statistical Analysis
Analysis of variance was performed using the GLM procedure of SAS® (Cary,
NC). Least significant difference test was used to compare means. Average pen weight
and feed conversion efficiency means were compared between treatments within each
treatment day. For all other variables, same sex means were compared within the
treatment day (MA vs. Vehicle).
RESULTS
Hatch, Body Weight Gain and Feed Conversion
Hatch data is shown in Table 1-1. Neither the hatch rate nor the number of dead
embryos was changed by vehicle or MA administration. At hatch, the average bird
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weight was similar for all treatment groups (Figure 1-1), and although the MA treated
groups appeared to be larger at week 4 and 5, there was no significant difference in the
average growth rate between the MA and vehicle treated birds (Figure 1-1). There was
not effect of day of injection on the cumulative feed conversion efficiency at six weeks
(Figure 1-2).

Muscle Characteristics
At six weeks of age, MA treatment on Day 15 or 18 had no effect on any of the
body weight measurements made for the male birds (Figure 1-3, 1-4, 1-5, 1-6).
Similarly, Day 18 treatment did not significantly altered the six-week old female broiler
body weight measurement or shank length. However, Day 15 administration increased
the breast wt. (14%, P<0.05, Figure 1-4) and shank length (7%, P<0.01, Figure 1-6) in
the female birds. Additionally, there was a trend to increase the live wt. (8%, P=0.093,
figure 1-3) and leg and thigh wt. (10%, P=0.079, figure 1-5) at six weeks of age. MA did
not change the shear force value for either the male or female Pectoralis major muscle
(Figure 1-7).

DISCUSSION
We have found that MA administration on Day 15, but not Day 18, of embryonic
development significantly altered the post hatch growth and development of female
broiler chickens. However, similar results were not found in the male bird. This may
indicate potential sexual dimorphic effects with respect to myostatin activity in the
chicken. Henry and Burke (1998) found that female broilers had a reduced number of
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myofibers per area in the Pectoralis superficialis at embryonic day 20 compared males.
This may indicate a mechanism limiting the proliferation of myoblasts in the female
embryo. Since myostatin has been shown to limit myoblast proliferation in vivo (Thomas
et al., 2000), changes in the sensitivity to myostatin may lead to differences during
embryonic development. Thus, the increased effect shown on muscle growth in the
female broiler may indicate such a relationship exists in the chicken. However, the
current study did not investigate the cause of the increased breast weight (hyperplasia vs.
hypertrophy), which would reveal the nature of the effects of MA treatment on the female
muscle growth and development.
From a production prospective, the sexually dimorphic growth patterns of male
and female broilers is well known. We found that in ovo MA treatment on Day 15
increased the breast muscle weight of the female broiler at harvest. This may provide a
method to lower the discrepancy between male and female broilers and increase total
productivity. Additionally, the increased muscle mass of female birds did not effect
tenderness of the Pectoralis muscle (Figure 1-7). This may indicate the ability of in ovo
MA treatment to be an effective method to increase muscle growth of the broiler with out
altering palatability.
In addition to the sex differences in response to the MA, we also observed an
increased response with Day 15 administration versus Day 18 administration. Kocamis et
al. (1999) found a significant increase in the expression of myostatin mRNA on
embryonic day 17 in the skeletal muscle. This may be an indication of the dose
dependence of the response during development. The increased expression of myostatin
observed on Day 17 of embryonic development (Kocamis et al., 1999) would indicate a
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greater concentration of the protein present on day 18. This may indicate the requirement
for a greater amount of MA to be administered on Day 18 to observe a similar response.
In female broiler chickens, we observed a greater increase in the breast muscle
than was reflected in the leg and thigh muscle (Figures 1-3 and 1-4). The breast muscle
of a chicken contains a greater proportion of white muscle fibers as compared to the leg
and thigh muscles. Carlson et al. (1999) showed that the highest myostatin expression
was found in muscles with the highest levels of white muscle fibers in mice. Therefore,
the greater increase in the mass of the breast muscle (14%) as compared to the leg and
thigh muscles (10%) may reflect a similar relationship between the development of
different muscle types in the chicken. Further investigation is required to assess the
distribution of muscle fiber types in the muscles of the chickens in response to MA
administration.
Myostatin may also interact with other members of the TGF-β family and/or
binding proteins of this family to regulate overall growth and development. In the
current study, in addition to the increase in muscle weight, there was also an increase in
the shank length of the female birds treated on Day 15, indicating a potential interaction
between the MA and other members of the TGF-β family. Evidence for such an
interaction is demonstrated between follistatin, an activin binding protein, and myostatin
in the regulation of muscle growth. Over expression of follistatin in mice led to a
significant increase in the muscle mass of the mice (Lee and McPherron, 2001).
Although no gross abnormalities were noted in the current study, this may
indicate a change in the mechanical qualities of the bones in the MA treated group. The
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potential interaction between the MA and bone growth warrants further investigation
because of potential implications to the poultry industry.
In the current study, we investigated the effects of in ovo administration of a MA
on the post hatch growth of broiler chickens. We found that administration on Day 15 of
embryonic development significantly increased the breast wt (14%) and shank length
(7%) and showed a tendency to increase the live wt (8%) and leg and thigh weight (10%)
of the female chickens without changing feed conversion efficiency. Coupling this
treatment with existing in ovo vaccination techniques provides a feasible method of
enhancing growth. Additionally, the enhanced effects in females could provide a method
to lessen the gender discrepancy in mixed-sex broiler production.
Table 1-1 - Hatchability
Treatment1
Eggs Treated
Number Infertile
Fertile Dead
Hatch
Male
Female
% Infertile
% Dead
% Hatch2

Control
D15 Veh D15 MA
D18 Veh D18 MA
Total
226
213
213
213
213
1078
8
7
5
3
7
30
21
13
18
14
25
91
197
193
190
194
180
954
96
94
95
95
98
478
101
99
95
99
82
476
3.5%
3.3%
2.3%
1.4%
3.3%
2.8%
9.3%
6.1%
8.5%
6.6%
11.7%
8.4%
90.4%
93.7%
91.3%
92.4%
87.4% 91.0%

1- Treatment Groups: Control- Uninjected Control, D15 – Injection on Day 15, D18 –
Injected on Day 18, Veh – Vehicle Injected, MA – Myostatin Antagonist Injected
2- % Hatch = No Live Hatched/ (No eggs injected – No infertile Treated)
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Figure 1-1- Average mixed-sex broiler weight measured as pen weight at end of each
week (n = 4 for each treatment) (Treatment Groups Control – uninjected control,
D15 Vehicle – Vehicle injected on Day 15, D15 MA – Myostatin Antagonist
injected on Day 15, D18 Vehicle – Vehicle injected on Day 18, D18 MA, Myostatin
Antagonist injected on Day 18).
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Figure 1-2 – Effect of in ovo MA administration on average mixed sex cummulative feed
conversion efficiency (mean ± SEM; n=4 for each treatment) at six weeks of age.
(Treatment Groups Control – uninjected control, D15 Vehicle – Vehicle injected on
Day 15, D15 MA – Myostatin Antagonist injected on Day 15, D18 Vehicle –
Vehicle injected on Day 18, D18 MA, Myostatin Antagonist injected on Day 18).
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Figure 1-3 – Effect of in ovo MA administration on live weight of male and female
broilers at six weeks of age (mean ± SEM; n=12 for sex within each treatment, p <
0.10 compared to same sex control). (Treatment Groups Control – uninjected
control, D15 Vehicle – Vehicle injected on Day 15, D15 MA – Myostatin
Antagonist injected on Day 15, D18 Vehicle – Vehicle injected on Day 18, D18 MA,
Myostatin Antagonist injected on Day 18.)
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Figure 1-4 – Effect of in ovo MA administration on breast weight of male and female
broilers at six weeks of age (mean ± SEM; n=12 for sex within each treatment, p <
0.05 compared to same sex control). (Treatment Groups Control – uninjected
control, D15 Vehicle – Vehicle injected on Day 15, D15 MA – Myostatin Antagonist
injected on Day 15, D18 Vehicle – Vehicle injected on Day 18, D18 MA, Myostatin
Antagonist injected on Day 18.)
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Figure 1-5 – Effect of in ovo MA administration on Leg and Thigh weight of male and
female broilers at six weeks of age (mean ± SEM; n=12 for sex within each
treatment, *- p < 0.10 compared to same sex control). (Treatment Groups Control –
uninjected control, D15 Vehicle – Vehicle injected on Day 15, D15 MA – Myostatin
Antagonist injected on Day 15, D18 Vehicle – Vehicle injected on Day 18, D18 MA,
Myostatin Antagonist injected on Day 18.)
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Figure 1-6 – Effect of in ovo MA administration on Shank length of male and female
broilers at six weeks of age (mean ± SEM; n=12 for sex within each treatment, *- p
< 0.01 compared to same sex control). (Treatment Groups Control – uninjected
control, D15 Vehicle – Vehicle injected on Day 15, D15 MA – Myostatin
Antagonist injected on Day 15, D18 Vehicle – Vehicle injected on Day 18, D18 MA,
Myostatin Antagonist injected on Day 18.)
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Figure 1-7 – Effect of in ovo MA administration on Pectoralis major shear force of male
and female broilers at six weeks of age (mean ± SEM; n=6 for sex within each
treatment). (Treatment Groups Control – uninjected control, D15 Vehicle – Vehicle
injected on Day 15, D15 MA – Myostatin Antagonist injected on Day 15, D18
Vehicle – Vehicle injected on Day 18, D18 MA, Myostatin Antagonist injected on
Day 18.)
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Chapter 2
The Effects of In Ovo rhIGF-I Administration on Expression of the Growth
Hormone Secretagogue Receptor (GHSR) During Chicken Embryonic
Development.
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INTRODUCTION
The secretion of growth hormone (GH) has been shown to be necessary for
normal postnatal growth in avian species (Vasilatos-Younken and Scanes, 1991). The
pulsatile release of GH by the anterior pituitary is primarily regulated by the interaction
of a pair hypothalamic factors, Growth Hormone Releasing Hormone (GHRH,
stimulatory) and Somatostatin (inhibitory) (for review see Muller et al., 1999). Recently,
a group of synthetic peptides and non-peptidyl analogues, collectively referred to as the
GH secretagogues (GHS), have been identified with the ability to induce GH secretion
without altering the release of other anterior pituitary hormones (for review see Smith et
al., 1997). It has also been demonstrated that GHS regulate the secretion of GH through
the recently identified GHS receptor (GHSR; Howard et al., 1996), independent of the
hypothalamic factors (Bowers et al., 1991)
The lack of detectable serum growth hormone until embryonic Day 17 (E17)
(Harvey et al., 1979) and pituitary GH mRNA until E18 (McCann-Levorse et al., 1992)
has led to the conclusion that early embryonic chicken development is GH-independent.
However, Harvey et al. (2000) found GH-immunoreactivity and GH Receptor (GHR)immunoreactivity throughout the peripheral tissues of E3, E6 and E7 chick embryos.
Additionally, GH mRNA expression from whole embryos has been detected during this
time period, prior to sotamotroph differentiation on E16 (Porter et al., 1995), suggesting
an anterior pituitary independent role for GH during early embryonic development
(Harvey et al., 2000, Murphy and Harvey, 2001). Expression of the GH regulated gene-1
(GHRG-1) in many, but not all tissues, on E8 shows active signaling through the GH-R
during embryonic development, supporting autocrine/paracrine function of GH (Harvey
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et al., 2001). Based on these recent findings, the mechanism (s) that regulates the
expression and secretion of GH during early embryonic development has to be
reevaluated. In the current study, we examined growth hormone secretagogue receptor
expression in the whole embryo during early embryonic development, and in the
pectoralis muscle during later embryonic development. Additionally, we have previously
demonstrated that in ovo administration of recombinant human Insulin-Like Growth
Factor-I (rhIGF-I) on E3 improved posthatch muscle development (Kocamis et al., 1998).
Therefore, we assessed changes in the expression pattern of the GHSR in response to in
ovo rhIGF-I administration on E3.

MATERIALS AND METHODS

Treatment and Sample Collection
Fertilized eggs (Cobb x Cobb) were obtained from Rocco Enterprises
(Harrisonburg, VA) and placed into a Buckeye incubator/hatcher (temperature 37 ± .5 C,
humidity 86 to 87%). In ovo administration of recombinant human IGF-I (rhIGF-I) and
sample collection was performed as previously described (Kocamis et al., 1999). Briefly,
eggs were injected once on embryonic Day 3 (E3) with 100 ng of rhIGF-I (R&D
Systems, Minneapolis, MN) dissolved in 100 µL of 10 mM Acetic Acid and 0.1% BSA.
Before injection, eggs were removed from the incubator, and the blunt end was sterilized
with 70% ethanol. A dental drill bit was used to make a hole through the shell, without
penetrating the chorio-allantonic membrane. A 22-gauge needle was used to puncture the
membrane and deliver the 100 µL of vehicle or rhIGF-I. The hole was sealed with an
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adhesive sticker before placing back in the incubator. Embryos and tissues were
harvested in compliance with an approved West Virginia University Animal Care and
Use Committee Protocol. All embryos were isolated and washed free of yolk, albumen
and extra-embryonic membranes with sterile nuclease-free water. On E0 to E6, whole
embryos (n=6 per day) were collected. Thoracic/abdominal halves of the embryos from
the lumbo-sacral level to the neck without head were collected on each of E 7 and E 8 (n=
6 per day). Pectoralis muscle was collected on each of E 9 to E 20 (n= 4 per day).

RNA Isolation and Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Total RNA was isolated from each sample following the TRI-Reagent (Molecular
Research Center Inc., Cincinnati, OH) modification of the guanidine
isothiocyanate/phenol-chloroform method originally described by Chomczynski and
Sacchi (1987). The quality of the RNA was assessed by formaldehyde agarose gel
electrophoresis with the visualization of the 18s and 28s rRNA bands. All RNA samples
were stored at –80°C. Reverse transcription was performed with 2 µg of total RNA, 2 µg
of random hexamer primers and Murine Maloney Leukemia Virus reverse transcriptase
(MMLV-RT) (Promega, Madison, WI).

Polymerase chain reactions were performed as

previously outlined (Kocamis et al., 2001). Briefly, 2 µL of the reverse transcription
reaction was added to a 50 µL of the PCR cocktail containing: 5 µL of 10x Taq buffer
(1.5 mM MgCl2 final concentration), 1 µL dNTPs (final concentration 0.2 mM each), 1
µL of sense and anti-sense primers (1 mM final concentation), 1 µL of Taq DNA
Polymerase (Display Systems Biotech, Vista, CA) and 41 µL of nuclease free water. For
the GHSR, touchdown PCR was used. This program consisted of a 5-min denaturation
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step (94°C), followed by 5 cycles in which the initial annealing temperature of 69°C was
reduced by 1°C per cycle, then 30 cycles in which the annealing temperature was 65°C.
The reaction was concluded with a 10-min extension step at 72°C. For the 18s-rRNA the
reaction was a standard PCR reaction. This program consisted of a 5-min denaturation
step (94°C), followed by 25 cycles in which the annealing temperature was 55°C. Again
the reaction was concluded with a 10-min extension step at 72°C. Gene specific primers
were designed based on published sequences of the chicken putative GHSR (genbank
accession # AJ309543) and chicken 18s rRNA sequence (genbank accession #
AF173612) and were obtained from Gibco BRL Inc. (Grand Island, NY). For GHSR, the
forward primer sequence was 5'-TCGCCATCTGCTTCCCTCTG-3' and the reverse
primer sequence was 5'-GCACCGTGAGGCAGAATAC-3'. Alignment with the putative
sequence published had a 262-bp PCR product corresponding to bases 125-387 of the
putative chicken GHS-R. The forward sequence of 18S rRNA was 5'CGGCGGCTTTGGTGACTCTA-3' and the reverse primer sequence was 5'CGCCGGTCCAAGAATTTCAC-3'. The two primers produced a 697 bp product and
corresponded to the bases 199-895 of the chicken sequence. All reactions were run on a
PTC-200 thermocycler (MJ Research, Watertown, MA). A water control (no cDNA)
reaction was run with each cocktail to assure that there was no contamination of the
components of the reactions. The identities of the PCR products were verified by
sequence analysis.
The amplified gene products were visualized by electrophoresis on 1.5% agarose
gels stained with ethidium bromide (0.2 mg/mL). The gene products were photographed
under UV light using a FluorChemTM Imaging System (Alpha-Innotech Corp., San
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Leandro, CA) and quantified by densitometric analysis of the photograph using
FlourChemTM Software (Alpha-Innotech Corp., San Leandro, CA). The densitometric
values for each gene product were normalized to densitometric values of the 18S rRNA
housekeeping gene. Regression analysis was performed by the GLM procedure of SAS
(Cary, NC). Statements of significance were based on P < 0.05 unless otherwise noted.

RESULTS

The control regression equation for GHSR was y = 0.141*day – (0.016*day2) +
(0.00058*day3) (r2=0.25, P<0.01). Figure 2-1a depicts the expression pattern for the
GHSR during embryonic development. Expression was low on E0 and remained at about
the same level through E4. There was a ~2.5 fold increase in expression on E5.
Although GHSR expression fluctuated during the mid-embryogenesis, it remained fairly
constant through E16 of incubation. Starting on E17, there was an increase in the
expression, which was followed by the highest expression in the breast muscle on E19.
The regression equation for the IGF-I treated group was y = (0.378*day) – (0.047*day2)
+ (0.0014*day3) (r2=0.15 P<0.05). The expression pattern is shown in figure 2-1b. As
with the control group, we found low expression on E0 and that it remained low until E4.
The expression of GHSR increased ~7 fold on E5 and continued to increase through E7.
Expression was reduced on E8 and remained fairly constant through E16. Then,
expression further increased on E17 and reached the highest level on E19 before reducing
on E20.
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Figure 2-2 shows the expression pattern of 18s rRNA during embryonic
development. 18s rRNA was used as the housekeeping gene in the current study. For
both the control and rhIGF-I treated groups, expression was constant throughout
embryonic development.

DISCUSSION
In the current study, we investigated the expression of the GHSR during chicken
embryonic development, with a particular focus on skeletal muscle. We found that
expression was low during the early embryonic period (Figure 2-1). Harvey et al. (2000)
found GH-immunoreactivity in most tissues and organs during this time of chicken
embryonic development. GHRH responsiveness of developing chicken embryos has
been shown to be very limited before E14 (Darras et al., 1994). Additionally, in
chickens, unlike mammals, thyrotropin-releasing hormone (TRH) induces GH secretion
from the pituitary (for review see Scanes et al., 1984). Identification of a cDNA
corresponding the GHSR from a pituitary cDNA library (Toogood et al., 1999) and
GHS’s ability to increase GH secretion both directly in the anterior pituitary and through
TRH in the hypothalamus (Geris et al., 2001) suggest the existence of a GHS-mediated
mechanism of GH release in the chicken. This leads to the possibility that the GHSR is
acting to regulate the expression of GH and GH may be functioning in an
autocrine/paracrine fashion in the peripheral tissues during embryonic development.
In ovo administration of GH has been shown to inconsistently alter the post hatch
muscle growth and development of chickens (Kocamis et al., 1999, Hargis et al., 1989).
This may be a result of the autocrine/paracrine nature of the GH found in early
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embryonic chicken tissues (Harvey et al., 2001). However, in ovo treatment with rhIGF-I
on E3 was found to significantly increase breast weight of 6-week-old broilers (Kocamis
et al., 1998). In the intact post-hatch bird, GH stimulated IGF-I secretion from the liver
and other tissues is required for normal growth (reviewed by Scanes, 1997). We
investigated the possibility that in ovo administration of rhIGF-I may have altered GH
synthesis through the recently identified GHSR. We found that there was an increase in
the expression of GHSR gene in the thoracic/abdominal section of the IGF-I administered
embryos between E6-E8. In the chicken embryo, primary muscle fiber formation begins
on E7 with secondary muscle fiber formation occurring between E7-E18 (Fredette and
Landmesser, 1991). During this period of embryonic development, both GH
immunoreactivity (Harvey et al., 2000) and GH-R mediated gene regulation (Harvey et
al., 2001) have been found in the developing muscle tissues. This challenged the widely
held tenant that early embryonic development is GH independent, and suggested the GH
may be acting in an autocrine/paracrine manner to regulate embryonic muscle
development. Thus, our finding suggests that IGF-I acts to increase the expression of the
GHSR during primary muscle formation, which in turn may act to increase the expression
of GH in the peripheral tissues (i.e. the muscle).
We found highest expression of the GHSR mRNA level on E19 in the pectoralis
muscle, concommitant with the dramatic increase in the serum GH concentration during
this time frame (Harvey et al., 1979). Although the contribution of peripherally derived
GH to circulating levels has been proposed to be very low compared to anterior pituitary
derived GH, this may suggest that peripheral tissues have a role in terms of regulating the
GH levels during late embryogenesis. Papotti et al., (2000) found GHS binding sites in a
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variety of human tissues including skeletal muscles. Increased expression of the GHSR
during the late stages of embryonic development indicate a potential role of the GHS
during the late pre-hatch development of the chick, an effect that may be independent of
GH.

The ability of GHS’s to induce GH secretion from the chicken (Bowers et al.,

1984, Geris et al., 2001) and identification of the endogenous ligand, ghrelin, for the
GHSR have shown another potential GH regulatory mechanism (Kojima et al., 1999).
Thus, it would be of interest to know what affect IGF-I administration has on the
synthesis and/or secretion of endogenous GHS’s, such as ghrelin.
The expression pattern of the GHSR gene during embryonic development
indicates an intricate role in the regulation of peripheral GH secretion during chicken
embryonic development. The increased expression on E7 following rhIGF-I
administration indicates that the increased posthatch muscle growth observed by Kocamis
et al., (1998) may have resulted from increased GH release originating from the
peripheral tissues during early embryonic development. As a future study, a real time
PCR approach should be used to measure the precise amount of mRNAs for GHSR gene
in response to in ovo administration of rhIGF-I. The data presented here indicate a critical
role for the GHSR and potentially its endogenous ligand in chicken embryonic
development.

69

Normalized Densitometric Units

a)

2.5

2
Values
Model

1.5

1

0.5

0
0

b)

1

2

3

4

5

6

7

9 10 11 12 13 14 15 16 17 18 19 20

Embryonic Day

2.5

Normalized Densitometric Units

8

2
Values
Model
1.5

1

0.5

0
0

1

2

3

4

5

6

7

8

9

10 11 12 13 14 15 16 17 18 19 20

Embryonic Day

Figure 2-1 - Steady-state levels of control (a) and rhIGF-I treated (b) group GHSR
mRNAs in whole embryo (E 0 to E 6, n= 6 per day), cranial halves (E 7 and E 8, n= 6
per day), and pectoralis muscle (E 9 to E 20, n= 4 per day) during chicken embryonic
development. The bands for GHSR mRNA were analyzed by densitometry and the
integration values (mean ± SD), after normalization to 18s rRNA, expressed as
normalized densitometric units at each sampling day.
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Figure 2-2 - Steady-state levels of control (a) and rhIGF-I treated (b) group 18s rRNA
mRNAs in whole embryo (E 0 to E 6, n= 6 per day), cranial halves (E 7 and E 8, n= 6
per day), and pectoralis muscle (E 9 to E 20, n= 4 per day) during chicken embryonic
development. The 18 rRNA bands were analyzed by densitometry and the arbitrary
densitometric units at each sampling day.
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Chapter 3
Expression of Ghrelin, the Endogenous Growth Hormone Secretagogue in
the Myostatin Knockout Mouse
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INTRODUCTION
Ghrelin, the recently identified endogenous ligand for the growth hormone
secretagogue receptor (GHSR), has been demonstrated in vitro (Kojima et al., 1999,
Hosoda et al., 2000) and in vivo both in rats (Date et al., 2000) and humans (Takaya et al.,
2000) to increase growth hormone (GH) release. In addition to the GH releasing role,
several GH-independent actions of ghrelin have been demonstrated. Tschöp et al. (2000)
found that a single injection of ghrelin daily resulted in an increased respiratory quotient
indicating increased utilization of carbohydrate and sparing of fat, reflected in the
increased fat mass of the treated animals. Additionally, ghrelin was shown to
significantly increase feed intake in humans (Wren et al., 2001b) and rodents (Wren et
al., 2001a). Stimulation of neuropeptide Y (NPY) and agouti related peptide (AGRP)
expression in the arcuate nucleus of the hypothalamus has been proposed as the
regulatory mechanism of feed intake (Kamegai et al., 2001; Lawrence et al., 2002). The
combination of induced feed intake and increased fat deposition has lead to significant
interest in the relationship between ghrelin and human obesisty.
Myostatin, also known as growth differentiation factor-8, a recently identified
member of the TGF-β family, has been demonstrated to be a negative regulator of muscle
growth (McPheron et al., 1997). In addition to muscle growth, recent studies have
indicated that loss of myostatin function reduced adipogensis. Attenuation of myostatin
activity through gene knockout (Lin et al., 2002) or expression of the myostatin
prodomain (Yang et al., 2001) resulted in a significant reduction in the accumulation of
fat during the growing period. Additionally, the significant reductions of fat mass in
crosses of myostatin knockout mice with Agouti lethal (Ay) or the Obese (ob/ob)

73

genotype suggesting an indirect role of myostatin on fat deposition, acting to alter
glucose metabolism (McPherron and Lee, 2002).

Cell specific activity of myostatin has

been demonstrated by alteration of adipocyte specific gene expression in 3T3-L1
preadipocytes cultures treated with myostatin (Kim et al., 2001).
In the current study, we have assessed changes in the expression of ghrelin in
several tissues of the myostatin knockout mouse. Based on the reduced fat deposition in
the myostatin knockout mouse, we expect that the loss of myostatin may down regulated
expression of ghrelin and thereby limit adipogensis in these mice.

MATERIAL AND METHODS
Animals
Nine-month-old male myostatin knockout (n= 3, SVJ/129) and control mice (n=
3, C57Bl/6) were generously provided by Metamorphix Inc., (Baltimore, MD).
Euthanasia of mice and subsequent tissue collections were performed in compliance with
an approved West Virginia University Animal Care and Use Committee protocol.
RNA extraction and RT-PCR
Total RNA was extracted from myostatin knockout and control mouse brain,
heart, liver, kidney, and skeletal muscle (pectoralis) tissues using the Tri-Reagent
(Molecular Research Center Inc., Cincinnati, OH) modification of the guanidine
isothiocyanate/phenol-chloroform method (Chomczynski and Sacchi, 1987). The RNA
concentration was estimated by absorbance at 260 nm in a Shimadzu spectrophotometer
(Model UV-1201, Columbia, MD). The integrity of the RNA was assessed by UV
visualization of ethidium-bromide stained intact 28S and 18S bands on a mini-agarose
gel. Samples of RNA were stored at -80ºC.
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Reverse transcription (RT) was performed using the murine maloney leukemia
virus reverse transcriptase (Promega, Madison, WI) as previously described (Kocamis et
al., 2002). For the PCR reaction, 2 µl of RT reaction mixture were added to 50 µl of
solution containing 5 µl of Taq buffer, 1 µl Taq DNA polymerase (Display Systems
Biotech, Vista, CA), 1 µl dNTPs (final concentration of each was 10 mM), 1 µl each of
forward and reverse primers, and 41 µl sterile nuclease-free dd H2O. For β-Actin, the
PCR reaction started with one cycle consisting of 94o C for 5 minutes, an annealing step
55o C for 1 minute and extension at 72o C for 1 minute. The first cycle was followed by
25 cycles consisting of 1 min intervals of 94o C, followed by 55o C, followed by 72o C.
The reaction was concluded with a 10-min extension step at 72°C. For ghrelin,
touchdown PCR was run. This program consisted of a 5-minute denaturation step at 94o
C, followed by 5 cycles in which the initial annealing temperature of 67o C was reduced
by 1o C per cycle, then 30 cycles in which the annealing temperature was 63o C.
Denaturation, extension and annealing time were programmed as described above. To
establish a linear range of amplification for each gene, several different cycle numbers of
PCR (10, 15, 20, 25 and 30 cycles) were run. As a control, a PCR reaction without cDNA (volume was replaced by water) was run, and no contamination was found in the
reaction mixtures (data not shown).
PCR primers
All PCR primers were synthesized by Gibco BRL Inc. (Grand Island, NY).
Primers for ghrelin were designed on the basis of published sequences of mouse ghrelin
(Kojima et al., 1999). The sequence of the forward primer was 5'TGAGCCCAGAGCACCAGAAA-3', and the reverse primer was 5'-
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GGCCTGTCCGTGGTTACTT-3'. Forward and reverse primers predicted a PCR product
of 285 base pairs (bp), which corresponds to bases (98-382) of the sequence. Forward
and reverse primers for β-actin were predicted to amplify a 285 bp product as previously
published (Yamamura et al., 1991), that was used as an internal standard to verify the
level of amplification. For β-Actin, the sequence of the forward primer was 5'TCATGAAGTGTGACGTTGACATCCGT-3', and the reverse primer was
5'-CCTAGAAGCATTTGCGGTGCACGATG-3'.
The amplified PCR products for each gene were visualized on 1.5 % agarose gels
stained with ethidium bromide. Products were analyzed by densitometry, and data should
therefore be considered to be semiquantitative. The identity of all PCR products was
confirmed by sequence analysis
Statistical Analysis
Probability of differences of least-square means was used to compare densitometric
values (General Linear Model procedure of SAS, SAS Institute Inc., Cary, NC).

RESULTS
β-actin expression was not different between the control and knockout tissues in any
of the tissues sampled (Figure 3-1). Ghrelin was detected in all tissues sampled (Figure
3-2) with the highest expression in the kidney, followed by the heart, liver, pectoralis
muscle and heart (Figure 3-2). Expression was similar between the control and knockout
tissues for brain, liver and kidney (Figure 3-2). Ghrelin expression was significantly
reduced in the heart tissue (P<0.05, Figure 3-2) and showed a tendency to be reduced in
the pectoralis (P= 0.07, figure 3-2) in the myostatin knockout as compared to the control.
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DISCUSSION
Myostatin, a negative regulator of muscle growth, has been recently found to effect
the distribution of fat in the growing mouse (Lin et al., 2002). Therefore, the current
study compared the expression of ghrelin, an adipogenic factor, in the tissues of the
myostatin knockout and wild type mouse. We found expression of ghrelin in all tissues
examined with highest expression in the kidney, with lower expression in the brain, liver,
pectoralis, and heart (Figure 3-2). Gnanapavan et al. (2002), using real-time PCR,
demonstrated a similar transcript distribution for ghrelin in the human tissues.
Attenuation of myostatin activity via gene knockout (Lin et al., 2002; McPherron
and Lee, 2002) or transgenic myostatin pro-domain expression (Yang et al., 2001) caused
a significant reduction in fat mass. In the current study, we found ghrelin expression to
be significantly reduced in the heart (P< 0.05) and tended to be reduced in the pectoralis
muscle (P = 0.07, figure 3-2) in the myostatin knockout mouse. Previous studies have
found myostatin expression in muscle tissue (McPherron and Lee, 1997) and in the
Purkinje fibers of the heart (Sharma et al., 1999). Taken together, this may indicate that
myostatin, acting in an autocrine/paracrine manner, regulates the expression of ghrelin.
The loss of myostatin had no effect on the expression of ghrelin in the brain, kidney and
liver (figure 3-2). To date, no studies have found the expression of myostatin in these
tissues. Tissue colocalization and effects of gene knockout/transgenics further support
the local effects of myostatin on ghrelin gene expression.
The loss of myostatin activity in two genetic models of obesity, the Ay and ob/ob
mice resulted in a partial reduction in fat accumulation (McPherron and Lee, 2002). In
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each case, the down regulation of ghrelin in the myostatin expressing tissues are
consistent with the observed changes in fat accumulation. In the Ay mouse, expression
of the agouti peptide in a variety of peripheral tissues has been proposed as causative
agent for the increased fat deposition (reviewed by Michaud et al., 1997). The increased
feed intake and fat accumulation as a result of ghrelin administration has been proposed
to be the result of increased agouti-related protein expression in the arcuate nucleus of the
hypothalamus (Kamegai et al., 2000). The reduction in ghrelin expression in the
peripheral tissues may attenuate ghrelin’s induction of agouti protein in the surrounding
tissues and thereby attenuate fat deposition. In the ob/ob mouse, the development of
obesity is the result of a mutation in the leptin gene, resulting in a truncated protein,
altering both the central and adipocyte specific effects of leptin on fat accumulation
(Huang and Li, 2000). In rats, intracentraventricular administration of ghrelin has been
demonstrated to antagonize leptin activity in the hypothalamus (Shintani et al., 2001).
The reduction of ghrelin expression with the loss of myostatin activity may act to remove
a positive signal on the adipocyte to increase adipose tissue growth and development.
Therefore, the local changes in the ghrelin expression, as a result of loss of myostatin
activity, may describe one mechanism by which myostatin regulates fat deposition.
Although circulating levels of ghrelin were not measured in the current study, the
lack of changes in ghrelin expression in the tissues that do not express myostatin
indicates that the changes in tissue-level ghrelin expression was not altered with the loss
of myostatin activity. A lack of systemic reduction in ghrelin levels may explain the only
partial suppression of fat accumulation observed in the myostatin knockout mouse
(McPherron and Lee, 2002). That is, maintenance of circulating ghrelin concentrations,
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i.e. gastric production, may act to allow accumulation of some fat in the myostatin
knockout mouse. The role of ghrelin in fat accumulation and growth of the myostatin
knockout mouse may allow a better understanding of the underlying mechanism by
which myostatin increases muscle mass and reduces fat accumulation.
The current study attempted to use the expression of ghrelin in the myostatin
knockout tissue to elucidate a potential mechanism by which fat accumulation is
attenuated in the myostatin knockout mouse. However, the exact mechanism regulating
this expression has yet to be fully elucidated. McPherron and Lee (2002) suggest that
myostatin may act either directly on the adipose tissue or indirectly by altering hormone
secretion in the muscle to regulate the fat accumulation. The current study would support
the indirect manner of myostatin regulating fat deposition. That is, loss of myostatin
acting at the level of the muscle and heart may down regulate the secretion of ghrelin and
thereby reduce the accumulation of fat. Further understanding of the relationship
between myostatin and ghrelin expression may provide insight into fat deposition, having
implications in both the medical and agricultural fields.
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Figure 3-1- Steady-state levels of β-actin mRNA in brain (B), heart (H), liver (L), kidney
(K), pectoralis (P) muscle of control (n= 3) and myostatin knockout mice (n=
3) tissues. The bands for β-actin were analyzed by densitometry and the
integration values (mean ± SD) were expressed in arbitrary units for each
tissue.
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CONCLUSIONS AND FUTURE STUDIES
The growth and development of muscle is regulated by a well-orchestrated
interaction between positive and negative stimuli resulting in the proper distribution of
the functional unit of support and locomotion. Gaining a better understanding of the
mechanisms regulating muscle growth and development will be useful to both the
improvement of animal production and treatment of human disease. In the work
presented here, we have tried to determine the relationship between a potential enhancer
of muscle growth, ghrelin, and a negative regulator of muscle growth, myostatin, in the
broiler chicken. Although the primary focus of this work was to improve muscle growth
in the meat type chicken, the implications of the work completed here may potentially
have implications well beyond improved broiler production.
In mammalian species, attenuation of active myostatin has been shown to greatly
increase muscle mass. In the chicken, the lack of an identifiable double muscled
phenotype and difficulties with gene knockout applications have limited the ability to
study attenuation of myostatin activity in the chicken. Taking advantage of the binding
of the prodomain of myostatin to the mature protein (Figure I2) to preclude receptor
binding has recently been found to significantly increase muscle mass of the mouse
(Yang et al., 2001). We have used in ovo administration of the prodomain of myostatin
during secondary muscle fiber proliferation to significantly increase muscle mass of
female chickens at six weeks of age. The significance of this data is twofold. First, this
indicates a similar role for myostatin in pre-natal muscle growth and development in the
chicken as has been observed in the mouse (McPherron et al., 1997). However, the
increased effect found in the female birds may indicate a sexually dimorphic manner of
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action in the chicken. Additionally, with the high proportion of broiler producers
(~80%) currently using in ovo vaccination, this method could provide a method that is
easily adaptable to the broiler industry to reduce the discrepancy between male and
female broilers during production greatly increasing the productivity of the individual
houses.
In contrast to the negative regulation of myostatin on muscle growth, GH has
been found to significantly increase muscle growth and development in mammalian
species (reviewed by Etherton and Bouman, 1998). Although similar results have not
been consistently demonstrated in the chicken, the absolute requirement of GH for
normal growth indicates a significant role in broiler growth and development (reviewed
by Scanes et al., 1986). Recently, Harvey et al., (2000) have found GH immunoreactivity
in a variety of cells of the early chick embryo indicating a role for GH during early
embryonic development in the chicken. However, they have not investigated the
mechanism regulating the secretion of GH during this timing of embryonic development.
The unresponsiveness of the chicken embryos to the hypothalamic secretory proteins,
GHRH and TRH, before embryonic day 14, indicates an independent mechanism
regulating this GH secretion (Darras et al., 1994). Identification of a cDNA
corresponding to the GHSR (Toogood et al., 1999) and GHS ability to increase GH
secretion both directly in the anterior pituitary and through TRH in the hypothalamus
(Geris et al., 2001) indicate the existence of a GHS mechanism in the chicken. This leads
to the possibility that the GHSR is acting to regulate the expression of GH in the
peripheral tissues during embryonic development. We have found increased expression
of the GHSR beginning on E5, which corresponds positively with the observed increase
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in GH immunoreactivity between E3 and E6 found by Harvey et al., (2000). Therefore,
we would suggest that the GHSR is acting to increase expression of GH during early
embryonic development. Although the endogenous ligand for the GHSR has yet to be
identified in the chicken (see below), the overlapping expression of the GHSR and GH
suggests that GHS administration during this time period would significantly increase the
release of GH in the early embryo, and thereby increase postnatal muscle growth and
therefore broiler productivity. Additionally, the increase in GHSR expression following
rhIGF-I administration on E3 may indicate a significant role for GH in the observed
increase in muscle growth (Kocamis et al., 1998).
As alluded to above, the role for the GHS in the secretion of GH during chicken
embryonic development indicates a significant role for the receptors endogenous ligand,
ghrelin, in growth and development of the chicken. However, attempts in this lab to
identify this ligand have proven futile. We have identified two changes in the approaches
used that could prove useful for the identification of this peptide. We have used PCR to
generate a partial sequence to be used as a probe in cDNA library screening to isolate the
cDNA representing chicken ghrelin. However, 3 sets of primers designed to the mouse
sequence and a set of primers based on chicken motilin (see identification of ghrelin as
motilin-related peptide above) were unable to generate a fragment showing homology to
any identified ghrelin sequences. Additionally, utilization of a 282-bp fragment of mouse
cDNA with 100% homology to mouse des-Gln14-ghrelin was unable to identify a ghrelin
clone with screening proventriculus, heart and adipose cDNA libraries and in southern
blot analysis of chicken genomic DNA. This indicated a significant divergence between
the mouse and chicken ghrelin genes. This conclusion is supported by the lack of
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significant homology between specices; for example there is only 29 % amino acid
homology between mouse and bullfrog ghrelin cDNA (Figure C1; Kiaya et al., 2001).
The common feature to all of the identified ghrelin sequences is the octanoylation of
amino acid 3, serine in the mammal species and threonine in the bullfrog. This
modification has been shown to be an absolute requirement for receptor binding
(Bernarek et al., 2000). Therefore, a reverse pharmacologial approach could be used to
identify the chicken ghrelin protein. That is, using a cell line transfected with the full
length mouse GHSR, or following isolation of the chicken full length sequence, one
could screen several chicken tissues to purify the proteins with the ability to bind to and
stimulate the GHSR in the chicken. Because of the divergence in the ghrelin sequences,
what we are suggesting is rather than utilizing nucleic acid techniques, one could use a
technique similar to the method used by Kojima et al. (1999), described above, to identify
ghrelin in the chicken.
Although we do not want to understate the difficulty in the establishment of the
cell lines, this process would allow screening of a variety of tissues in the chicken
without requiring extensive processing, i.e. construction of the cDNA library. This
process could eliminate the second complication that may have limited our ability to
identify this ligand in the chicken. We had used mammalian data to postulate that
expression of ghrelin would be greatest in the proventriculus, i.e. the glandular region of
the chicken stomach. Using a pool of mRNA from the proventriculus at weeks 1 to 5, the
rapid growing phase of the chicken’s life, we constructed a cDNA library and screened it
for the ghrelin cDNA sequence. This library was found to have an accepible titer, 3.1 x
109 pfu/mL, and contained relatively large inserts, average size at about 900 bp.
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Additionally, the successful analysis of 134 ESTs has identified cDNA of proteins
specific to the stomach (see the appendix). However, part of the inability to identify
ghrelin may have stemmed from looking in the incorrect tissue. A recent study has found
no ghrelin immunoreactivity in the mucosal cells of the proventriculus, rather a rat
antibody showed binding only in the hypothalamus (Ahmed and Harvey, 2002). This
would suggest future attempts to characterize ghrelin at the nucleic acid level must
include analysis of this region of the brain.
Finally, we attempted to determine if a relationship between myostatin and
ghrelin exists in the determination of muscle and fat mass of the mouse. In this study we
used RT-PCR to determine the expression of ghrelin in several tissues of the myostatin
knockout mouse. We found a reduction in ghrelin expression in the heart and pectoralis
muscle of the myostatin knockout mouse. Although these data represent a preliminary
assessment of the alteration in ghrelin expression, we have not looked at the active
protein levels in the serum. They may indicate an interaction between ghrelin and
myostatin in the partitioning of the body tissues during growth and development. That is,
loss of myostatin activity in the mouse (myostatin knockout mouse; McPherron and Lee,
2002) and in double muscled cattle (Bass et al., 1999) leads to a much leaner animal with
a significant increase in muscle mass. The increased muscle mass is proposed to result
from the loss of anti-proliferative effects of myostatin on the muscle cells (reviewed by
Sharma et al., 2001). However, the identification of the myostatin mutation in cattle that
do not show double muscling indicated the presence of additional factors involved in the
development of this phenotype (Smith et al., 2000). The data collected here may provide
evidence for the involvement of ghrelin as one of these factors. For example, in the
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South Devon breed of cattle, not considered to be double muscled, the myostatin gene
shows the same mutation identified in the Belgian Blue breed, the poster child of double
muscling. We may speculate that ghrelin expression is not attenuated in the muscle of
the South Devon breed resulting in either direct or indirect effects on muscle growth.
Ghrelin may act directly on the muscle to cause reduced proliferation and thereby
mediate the loss of the double muscled phenotype. Alternatively, ghrelin may cause a
shift in the metabolism of the cells during muscle growth. That is, ghrelin may act on the
fat cells to increase energy and nutrient uptake by the fat, causing a shift from lean to fat
tissue deposition and thereby not allowing for as significant increase in the muscle mass.
In either case, further research remains to be conducted. The direct effects of
ghrelin could be determined by treatment of muscle cells in culture with exougenouslysupplied ghrelin. The cells could not only be monitored for changes in proliferation, but
also for nutrient utilization. However, the indirect effects would be significantly more
difficult to assess. One could choose to use a co-culture system with fat and muscle cells
incubated together. Although, this would allow assessment of the interactive effects of
ghrelin, however, it would remove the systemic effects from the equation. Therefore, a
more complete picture of the effects could be gathered by measuring the effects of
ghrelin administration on muscle during growth and developmentOur data suggests a
reduction in ghrelin expression in the mouse muscle following loss of myostatin activity.
The mechanism resulting in the reduction of ghrelin expresion may involve more factors
beyond the limited scope of the current study. Although much work has been done in the
mouse with attenuation of myostatin activity, to date no complete hormone profile has
been published. The observed decrease in the fat deposition concurrent with increased
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muscle mass of the myostatin knockout mouse indicates that a variety of changes in the
hormone profile of the animal have occurred, which have yet to be fully elucidated.

Figure C1- Aligment of Bullfrog Ghrelin amino acid sequence with the identified
Mammal Ghrelin Sequences.
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Appendix 1

1
2
3
4
5
6

Chicken Proventriculus EST Clone Identities
Total 134 EST Sequences
117 Uniques Sequences Representing 63 Identified Genes
64 Unknown Sequences
Clone ID

Gene Identity

Score

Expected

Homology

% Homology

1-47

60S Ribosomal Protein L34 (Mouse)

291

3.00E-76

296/345

85%

1-27

Chicken CaM gene encoding calmodulin

345

1.00E-92

221/242

91%

1-28

Chicken mRNA for acidic ribosomal protein P1

494

1.00E-137

259/261

99%

2-87

Chicken mRNA for ribosomal protein L5

716

0

431/452

95%

1-78

Chicken mRNA for ribosomal protein L5

755

0

429/440

97%

1-16
1-66

Chicken neuropeptide Y
Felis catus cell-type fibroblast mutant beta-glucuronidase (GUSB)

75.8
52

3.00E-11
5.00E-04

38/38
43/49

100%
87%

1-52
2-33

G.domesticus mRNA BTG1
Gallus domesticus helix-loop-helix transcription factor sequence

753
565

0
1.00E-158

420/427
348/365

98%
95%

1-77

Gallus gallus beta-actin mRNA

779

0

443/452

98%

2-44

Gallus gallus calmodulin mRNA

597

1.00E-168

376/397

94%

1-43

Gallus gallus clone CW nonLTR retrotransposon CR1

75.8

2.00E-11

61/69

88%

2-59

Gallus gallus cPgA mRNA for pepsinogen A

545

1.00E-152

364/393

92%

1-09

Gallus gallus cPgA mRNA for pepsinogen A

545

1.00E-152

343/361

95%

1-65

Gallus gallus cPgA mRNA for pepsinogen A

682

0

417/437

95%

2-50

Gallus gallus cPgA mRNA for pepsinogen A

607

1.00E-171

371/390

95%

1-25

Gallus gallus cPgA mRNA for pepsinogen A

696

0

414/427

96%

1-70

Gallus gallus cPgA mRNA for pepsinogen A

555

1.00E-156

308/316

97%

1-94

Gallus gallus cPgA mRNA for pepsinogen A

761

0

438/447

97%

2-45

Gallus gallus cPgA mRNA for pepsinogen A

626

1.00E-177

338/347

97%
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Clone ID

Gene Identity

Score

Expected

Homology

% Homology

2-71

Gallus gallus cPgC mRNA for pepsinogen C

615

1.00E-173

373/390

95%

2-70

Gallus gallus domesticus H+ K+ ATPase beta subunit mRNA

509

1.00E-142

346/372

93%

2-48

Gallus gallus kinase related protein gene

656

0

373/391

95%

2-69

Gallus gallus kinase related protein gene

678

0

391/407

96%

1-60

Gallus gallus kinase related protein mRNA

743

0

435/451

96%

1-19

Gallus gallus kinesin light chain mRNA

234

5.00E-59

125/126

99%

2-37

Gallus gallus mitochondrial genome

539

1.00E-151

299/306

97%

1-76

Gallus gallus mitochondrial genome

787

0

407/409

99%

2-10

Gallus gallus mitochondrial genome

583

1.00E-164

304/306

99%

1-41

317

3.00E-84

187/194

96%

1-68

Gallus gallus mitochondrion, complete genome
Gallus gallus mRNA for human bbc1 (breast basic conserved gene)
product homologue

660

0

388/401

96%

1-12

Gallus gallus mRNA for matrix GLA protein

700

0

374/377

99%

2-38

Gallus gallus NADH dehydrogenase mRNA

640

0

358/368

97%

1-92

Gallus gallus otokeratin mRNA

817

0

450/456

98%

1-20

Gallus gallus p95 paxillin-kinase linker mRNA

414

1.00E-113

242/248

97%

1-13

Gallus gallus peptide elongation factor 1-beta

317

4.00E-84

183/187

97%

1-89

H.sapiens (xs81)

95.6

4.00E-17

78/87

89%

1-75

Homo sapiens C9orf10 protein

345

2.00E-92

283/315

89%

1-03

Homo sapiens eosinophil chemotactic cytokine

105

4.00E-20

140/169

82%

1-22

Homo sapiens eosinophil chemotactic cytokine

83.8

1.00E-13

81/94

86%

1-50

Homo sapiens eosinophil chemotactic cytokine (TSA1902)

83.8

1.00E-13

99/119

83%

1-72

Homo sapiens eosinophil chemotactic cytokine (TSA1902)

99.6

2.00E-18

132/159

83%

1-87

Homo sapiens eosinophil chemotactic cytokine (TSA1902)

52

5.00E-04

53/62

85%

1-51

Homo sapiens GAJ protein (GAJ)

73.8

9.00E-11

109/132

82%
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Clone ID

Gene Identity

Score

Expected

Homology

% Homology

1-71

Homo sapiens geranylgeranyl pyrophosphate synthetase

194

5.00E-47

327/403

81%

2-11

Homo sapiens glutamyl-prolyl-tRNA synthetase (EPRS)

198

4.00E-48

223/264

84%

2-01

Homo sapiens hypothetical protein DKFZP586F1318

107

1.00E-20

129/154

83%

1-30

Homo sapiens insulin-like growth factor binding protein 7

89.7

2.00E-15

136/165

82%

2-43

Homo sapiens KIAA0970 protein (KIAA0970)

151

6.00E-34

272/338

80%

2-67

327

7.00E-87

259/287

90%

67.9

9.00E-09

61/70

87%

2-26

Homo sapiens profilin 2 (PFN2), transcript variant 1
Homo sapiens protein disulfide isomerase related protein (calciumbinding protein, intestinal-related) (ERP70)
Homo sapiens protein tyrosine phosphatase type IVA, member 1
(PTP4A1)

172

2.00E-40

212/255

83%

1-57

Homo sapiens RAB2, member RAS oncogene family (RAB2)

218

4.00E-54

119/122

97%

1-14
1-05

Homo sapiens ribosomal protein L32 (RPL32)
Homo sapiens ribosomal protein L9 (RPL9)

283
250

7.00E-74
1.00E-63

305/359
285/338

84%
84%

1-26

Homo sapiens signal peptidase 12kDa

141

5.00E-31

161/191

84%

2-25

Homo sapiens similar to DKFZP586O0120 protein

151

6.00E-34

110/122

90%

2-24

Homo sapiens similar to dynein, cytoplasmic, light polypeptide

289

1.00E-75

254/290

87%

1-69

Homo sapiens similar to voltage-dependent anion channel 1

351

4.00E-94

369/431

85%

1-04

Homo sapiens spermine synthase (SMS)

260

1.00E-66

312/371

84%

1-48

Homo sapiens stromal cell derived factor receptor 1 (SDFR1)
Homo sapiens, ATP synthase, H+ transporting, mitochondrial F1
complex, delta subunit

73.8

1.00E-10

59/65

90%

125

4.00E-26

177/215

82%
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1.00E-23

127/150

84%

1-08

Mus musculus KDEL containing protein 1 (Kdel1),
Mus musculus nuclear receptor subfamily 2, group F, member 2
(Nr2f2)

46.1

0.017

38/42

90%

1-85

Mus musculus ribosomal protein L27a (Rpl27a)

200

9.00E-49

355/436

81%

1-17

NAD-Dependent Methanol Dehydrogenase (Human)

202

2.00E-49

275/330

83%

2-75

1-54
2-29
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Clone ID

Gene Identity

Score

Expected

Homology

% Homology

1-91

Rattus norvegicus ribosomal protein L35a (Rpl35)

202

2.00E-49

252/301

83%

1-02

Ribosomal protein L27a (Mouse)

172

2.00E-40

201/239

84%

248

3.00E-63

192/213

90%

1-62
Ribosomal Protein L38 (Mouse)
1-01, 1-07, 1-10, Unknown
1-11, 1-15, 1-23,
1-29, 1-31, 1-32,
1-33, 1-34, 1-35,
1-36, 1-37, 1-38,
1-39, 1-40, 1-42,
1-45, 1-49, 1-53,
1-55, 1-56, 1-63,
1-64, 1-67, 1-74,
1-79, 1-80, 1-81,
1-82, 1-90, 1-93,
1-95, 1-96, 2-08,
2-27, 2-32, 2-34,
2-35, 2-39, 2-40,
2-41, 2-42, 2-47,
2-52, 2-53, 2-54,
2-55, 2-56, 2-57,
2-58, 2-64, 2-65,
2-66, 2-72, 2-73,
2-74, 2-76, 2-79,
2-80, 2-83, 2-90,
2-91
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Appendix 2
Uncoupling Protein 3 in the Rainbow Trout (Oncorhynchus mykiss):
Sequence, Variants and Association with the AvaIII SINE element.
ABSTRACT
A Rainbow Trout Uncoupling Protein 3 (UCP3) cDNA clone, encoding a 309
amino acid protein, was cloned and sequenced from a liver cDNA library. Two different
splice variants designated UCP3-v1 and UCP3-v2, were found through liver cDNA
library screening using Rainbow Trout UPC3 cDNA clone as probe. UCP3-v1 has 3
insertions in the UCP3 cDNA: the first insertion (133 bp), the second insertion (141 bp),
and the third insertion (370 bp) were located 126 bp, 334 bp, and 532 bp downstream
from start codon respectively. UCP3-v2 contained a single insertion, identical in
sequence and location to the second insertion of UCP3-v1. UPC3, a mitochondrial
protein, functions to modulate the efficiency of oxidative phosphorylation. Human and
rodent UCP3s are highly expressed in skeletal muscle and brown adipose tissue. In
contrast to mammalian studies, RT-PCR and Southern Blot Analyses of the Rainbow
Trout demonstrated that UCP3 was not restricted to skeletal muscle and adipose tissue.
Expression was detected in all tissues examined with the highest levels found in liver and
heart. UCP3, UCP3-v1, and UCP3-v2 all contain an Ava III Short Interspersed Element
(SINE), located in the 3’-UTR. PCR using primers from the Ava III SINE and the UCP3
3’-UTR region indicate that the UCP3 cDNA is structurally conserved among Salmonids
and that these primers may be useful for Salmonid species genotyping.
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INTRODUCTION
Short interspersed repetitive elements (SINEs) are non-viral retrotransposons
incorporated into the genome of a wide variety of organisms (Singer, 1982). SINEs are
commonly referred to as tRNA pseudogenes as a result of their homology to tRNA
sequences (Okada, 1991). In salmonid fish, three classes of SINE elements have been
discovered: SmaI family, HpaI family and FokI family. An additional group, the HpaIrelated AvaIII family, is common to many salmonid species (Kido et al., 1994). SINE
elements, by sequence and quantity, are used as phylogenetic markers (Murata et al.,
1996), and the identification of a common SINE element in the transcribed portion of a
particular gene may indicate the evolutionary conservation of the gene.
Over the past 30 years, there has been extensive research into the mechanism of nonshivering thermogenesis and the importance of brown adipose tissue (BAT) in the
temperature regulation of infants (for review see Nicholls, 2001). This work led to the
identification of uncoupling protein 1 (UCP1) in the BAT, a mitochondrial carrier protein
with the ability to increase heat production by altering the proton permeability of the
inner mitochondrial membrane (for review see Villarroya, et al., 2001). Subsequently,
two other members of the UCP family have been identified, UCP2 and UCP3. UCP2,
classified according to the aa sequence homology to UCP1, is expressed in a variety of
tissues and is thought to serve a similar function to UCP1, but its true function is yet to be
fully elucidated (for review see Ricquier and Bouillaud, 2000). An additional UCP
(UCP3),identified by the 57% aa homology to UCP1, was found to be primarily
expressed in skeletal muscle with lower expression in BAT and cardiac muscle. (Fleury
et al., 1997). In addition to the proton shunting ability, recent studies indicate a
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significantly different role for UCP3 in the regulation of fatty acid metabolism. During
periods of starvation, i.e. a shift in the muscle to primarily lipid catabolism, UCP3
expression is upregulated in the muscle, with the fast glycolytic muscle showing the
greatest response (Hildebrant and Neufer, 2000). In the mouse, the connection between
UCP3 and fatty acid metabolism is further reflected in the mapping of markers of obesity
and hyperinsulemia in close proximity to the UCP3 gene locus on chromosome 7 (Fleury
et al., 1997).
Two alternatively spliced forms of the UCP3 gene have been identified in human
skeletal muscle. The long transcript (UCP3L) includes a small potion of the 6th exon and a
7th exon, while the short transcript (UCP3S) includes only the 1st 6 exons (Solanes et al.,
1997). Based on the cDNA sequences of the two variants, human UCP3 is represented
by proteins of 312 aa (UCP3L) and 275 aa (UCP3S) found on the inner mitochondrial
membrane (Solanes et al., 1997). However, in the mouse and human, research indicates
that only the long transcript is translated into an active protein (for review see Harper et
al., 2001).
In a preliminary experiment, we sought to determine identity of gene transcripts
containing the HpaI-Related AvaIII SINE element in the Rainbow Trout. From this
work, we had isolated a partial sequence of the Rainbow Trout UCP3. With the potential
for metabolic regulatory roles for UCP3 in the Rainbow Trout, we decided to look
specifically at this gene transcript. Therefore the objective of the current work, was to
determine the full length UCP3 sequence in Rainbow Trout, tissue distribution, identity
of any splice variants and conservation of the AvaIII SINE element found in the 3’ UTR
of the UCP3 gene in other salmonid species.
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MATERIALS AND METHODS

Determination of Identity of Genes Expressing AvaIII SINE

A liver cDNA library, prepared in λ ZapII vectors, were kindly provided by Dr.
Joe Brunelli of Washington State University. During routine EST screening of this
library, a clone was isolated that contained a putative AvaIII SINE. A single PCR primer
was designed using GeneTools 1.0 (BioTools, Inc., Edmonton, AB, Canada), within the
SINE element. The primer sequence was 5’-TTAACCCAACCCCTCTGAATCAGAG3’, which was purchased from GIbco BRL (now Invitrogen, Corp., Carlsbad, Ca). PCR
screening of the excised cDNA library, using the AvaIII primer and either the T7 or T3
promoter primers (Promega, Madison, WI), was performed as follows. Twenty-four µL
of a PCR cocktail containing: 2.5 µL of 10x Taq buffer (1.5 mM MgCl2 final
concentration), 0.5 µL dNTPs (final concentration 0.2 mM each), 1 µL of AvaIII primer
(4 ng/mL final concentation) and 5 µL T3 or T7 primer (4 ng/mL final concentration), 0.5
µL (2.5 U) of Taq DNA Polymerase (Display Systems Biotech, Vista, CA) and 14.5 µL
of nuclease free water was added to 1 µL excised liver cDNA library phagemid. The
PCR started with one cycle consisting of denaturing (94°C) for 4 min, annealing (55°C)
for 1 min, and extension (72°C) for 1 min. The first cycle was followed by 30 cycles
consisting of 1 min intervals of denaturing at 94°C followed by annealing at 55°C
followed by extension at 72°C. These cycles were followed by a final 10 min extension
step (72°C). The products were separated by gel electrophoresis (1% agarose) and
stained with ethidium bromide to determine the sizes of the amplicons (see Figure 1).

114

The PCR products were subject to TA Cloning (pCR 4 Vector, Invitrogen, Corp.,
Carlsbad, Ca), and plasmid insert size was determined by EcoRI restriction digestion and
gel electrophoresis analysis. Plasmids containing unique amplicons were sequenced
using the Big Dye Terminator method (PE Biosystems Co., Foster City, CA) on an
automated ABI 310 DNA sequencer (PE Biosystems Co., Foster City, CA). The identity
of each insert was determined by using the NCBI Blast search of the Gen Bank Data
Base. Plasmid DNA was stored at –20ºC.

Rainbow Trout Liver cDNA Library Screening For UCP3
The UCP3 cDNA was found among the expressed sequences cloned and
determined to contain an AvaIII SINE. Because this gene had not been characterized in
the Rainbow Trout, we chose to use hybridization based cDNA library screening in an
attempt to isolate the full-length expressed sequence. Briefly, plaque DNA from the
cDNA library was fixed to nylon membranes to allow hybridization with a 32P labeled
probe. Following the pre-hybridization wash, the membranes were hybridized overnight
at 42°C. Following the hybirdization, three washes of each membrane were used to
remove unbound probe, these consisted of 2x SSC with 0.1% SDS at room temperature,
0.5x SSC with 0.1% SDS at 55°C, and 0.1x SSC with 0.1% SDS at 65°C. Following the
washes, the membranes were exposed for at least 3 hrs to Bio-Max film (Eastman Kodak
Co., New Haven, CT) at –80°C. Probe DNA was generated from the plasmid DNA
isolated in the preliminary experiment. Following EcoRI restriction digestion of the
plasmid DNA, the insert fragment (~1400 bp) was gel purified using the Freeze ‘N
Squeeze column method (Bio-Rad, Hercules, CA). This fragment was labeled with 32P
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using Amersham dCTP Ready-To-Go Labeling beads according to the manufacturer’s
protocol (Amersham Biosciences, Piscataway, NJ). Approximately 3.0 x 106 plaques
were screened. Fifteen positive plaques, which had been subject to a second and a third
rounds of screening, were isolated for sequence analysis.
Once the individual positive plaques were isolated, the phagemid vector
(pBluescript) was excised using the ExAssist Helper Phage following Stratagene’s
protocol (Stratagene, La Jolla, CA). The resulting plasmid was sequenced from both
forward and reverse directions, using the T7 and T3 promoter primers and the Big Dye
Terminator Reaction (see above). A contig of the two sequences was constructed for
each clone using GeneTools 1.0 (BioTools, Edmonton, AB, Canada). For clones not
showing overlapping sequence, primer walking was preformed to allow determination of
the full-length sequence.

Tissue Distribution of UCP3 in Rainbow Trout
Reverse transcription-polymerase chain reaction (RT-PCR) was used, in
combination with Southern Blot analysis to determine the tissue distribution of the UCP3
in the Rainbow Trout. Total RNA was isolated from adult (~2 yr old) mixed-sex rainbow
trout following the TRI-Reagent (Molecular Research Center Inc., Cincinnati, OH)
modification of the guanidine isothiocyanate/phenol-chloroform method as described by
Chomczynski and Sacchi (1987). The quantity of RNA will be estimated using the
absorbance at 260 nm on a Shimadzu Spectrophotometer (Shimadzu Corp., Columbia,
MD). The quality of the RNA was assessed by formaldehyde agarose gel electrophoresis
with the visualization of the 28s and 18s rRNA bands. All RNA samples were stored at
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–80°C. RNA was isolated from the brain, heart, liver, kidney, spleen, skeletal muscle,
pituitary, stomach, intestines, eye, skin and adipose tissues. Reverse transcription was
performed with 2 µg of total RNA, 2 µg of oligo-dT primers and Murine Maloney
Leukemia Virus reverse transcriptase (MMLV-RT), as previously described (Kocamis et
al., 2001). Taq polymerase (Display Systems, Los Angeles, CA) and gene specific
primers were used for gene product amplification with the reaction set up as described
above. A touchdown reaction was run with an initial annealing temperature of 68ºC,
reducing by 1ºC for 10 cycles and then an additional 25 cycles with an annealing
temperature at 58ºC. The products were separated by 1% agarose gel electrophoresis
containing 200 ng/mL Ethidium Bromide and visualized and photographed with the
FlouroChem Imaging System (Alpha-Innotech, Corp, San Leandro, CA). The identity of
the products was verified by Southern Blot analysis.

Conservation of the UCP3 Ava III SINE in Other Salmonid Species
Genomic DNA samples were isolated for Rainbow Trout (Kamloop, Red Band,
Cutthroat and Steelhead strains), Brook Trout, Brown Trout, Artic Char, Atlantic Salmon,
and Pacific Salmon using Bio-Rad’s AquaPure Genomic DNA Isolation Kit (Bio-Rad,
Hercules, CA). This DNA was subject to PCR amplification for the AvaIII SINE located
in the 3`-UTR of the Rainbow Trout UCP3 gene. The PCR reaction was setup as
decribed above, using 1 µL of genomic DNA as the template. The PCR reaction
consisted of 35 cycles with an annealing temperature of 60°C and primers specific to the
SINE element in 3’ UTR of UCP3. The upper primer (5'-GGGGACCTCTAGCCATTC3') and lower primer (5'-TCAACTGAAATGTGTCCTCCGC-3') were designed to
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amplify a 201-bp product of UCP3 3’-UTR including the AvaIII SINE. The products
were separated by 1% agarose gel electrophoresis containing 200 ng/mL Ethidium
Bromide and visualized and photographed with the FlouroChem Imaging System (AlphaInnotech, Corp, San Leandro, CA). The identity of the products was verfied by southern
blot analysis. The probe used for the Southern analysis was a sub-clone from the 3’ UTR
of the Rainbow Trout UCP3 cDNA labeled using the Ready-to-go Labeling beads
(Amersham Biosciences, Piscatway, NJ) as previously described.

RESULTS AND DISCUSSION

Table 1 shows the identity of the three unique sequences isolated through EST
and PCR screening of the RT Liver cDNA library. The 28S Ribosomal RNA (RTI#12)
represents the original AvaIII SINE identified through the EST screening of the cDNA
library. PCR screening and cloning subsequently lead to the identification of two
additional unique sequences containing an AvaIII SINE (see Table 1). As such, these
genes may be located in identifiable regions of the genomic DNA linked to evolutionary
or phenotypic changes in Salmonids (Murata et al., 1996). To investigate this possibility
further, we felt the potential role of UCP3 in metabolic regulation would make it an
excellent candidate for association with phenotypic changes. However, the identification
of a novel gene product (unknown in Table 1) containing a phylogenic marker could
represent a more useful marker specific to Salmonids, a consideration that is currently
being investigated in our laboratory. However, the role of UPC3 as a potential metabolic
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regulator in the growing animal lead us to further investigate this previously unreported
uncoupling protein from a cold water fish (Rainbow Trout).
Using a cloned partial sequence isolated by PCR screening of the liver cDNA
library, we were able to identify 15 clones that hybridized specifically to the UCP3 probe.
Thirteen of the 15 clones were found to contain the identical 1685 bp sequence (see
figure 2) in which the longest open reading frame encodes for a 309-aa polypeptide with
69% aa homology to porcine (GenBank accession no. AAD33396) and canine (GenBank
accession no. Q9N2I9) UCP3s. The cDNA identified showed the Rainbow Trout UCP3
(Figure 2) is transcribed as a 1685 bp mRNA consisting of a 101-bp 5' untranslated
region, a 930-bp open reading frame, and a 654-bp 3'-untranslated region. We have
identified the AvaIII SINE as being an 111-bp sequence located in the 3'-UTR. The two
additional clones identified (UCP3v1 and UCP3v2) were identified as potential splice
variants of the UCP3 gene. UCP3v1 contained three insertions, while UCP3v2 contained
only one, which was identical in location in sequence to the second insertion in UCP3v1
(see Figure 2). The first insertion was found 126-bp downstream from the translation
start codon, and was identified to be 133-bp in length. The second insertion was 134-bp
in length and was located 334-bp downstream from the start codon, not including the first
insert. The final inserted sequence was 370-bp long and was found 533-bp from the start
codon. Following the GT-AG sequence found at the ends of each of the insertions (see
Figure 2), we can conclude that these are the result of splice variations in the UCP3 gene.
Following the open reading frame of the UCP3 cDNA, each of the variants would result
in the translation of a truncated form of the protein. This may support a similar situation
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as in humans in which a truncated form of UCP3 (UCP3S), results from splice variation
and has been suggested to be a non-functional form of the protein (Solanes et al., 1997) .
The similarity in the aa sequence between the mammalian homologues (swine and
dog) would suggest a similar structure for the UCP3 identified in the current study and
therefore we would suggest, based on the homology, that the protein in the RT would
have a conserved function. The next point was to determine the tissue distribution of
UCP3 in the Rainbow Trout tissues. Using reverse transcription-polymerase chain
reaction we found that UCP3 was expressed in a wide variety of tissues scanned (Figure
3). This was a somewhat unexpected result, as previous reports have shown UCP3
expression to be limited to skeletal muscle and BAT, with significantly lower expression
in the cardiac muscle (for review see Fleury et al., 1997). In the present study, the
greatest expression was found in the liver followed by the gastrointestinal organs
(stomach and intestines), which may suggest a significantly different role for the UCP3 in
metabolic regulation in the Rainbow Trout. In tuna and lamnid sharks, a heat exchange
system surrounding the viscera has been suggested to have a key role in maintenance of
elevated organ temperature increasing the digestive capabilities of the fish (for review see
Carey et al., 1971). In a similar manner, we can suggest a similar role for the expression
of UCP3 in and around the visceral organs of the rainbow trout, a theory that could be
tested by comparing the expression of this gene in trout reared under a variety of
temperatures.
A final consideration was the conservation of the AvaIII SINE element found in
the 3’UTR of the Rainbow trout UCP3 gene. Using PCR and Southern Blot analysis, we
were able to demonstrate the presence of this AvaIII SINE in a variety of salmonid
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species (Figure 4). However, this investigation revealed two interesting results. First,
we found in addition to the expected 201-bp fragment, found in all Rainbow Trout strains
and the Pacific salmon, that a 178-bp fragment was found common to all the Salmonid
species (see Figure 4). The Southern Blot data indicate that this fragment shares close
homology to the 201-bp fragment, and thus may indicate the presence of a closely related
gene in all salmonid species. Solanes et al. (1997) suggested based on the high homology
and close localization on chromosome 11, that UCP3 resulted from a duplication event of
UCP2. Although we have not specifically determined either the location of the gene or
the identity of the sequence around the 178-bp band, this may indicate a similar event
occurred in the salmonids. Additionally, in the Brook Trout, Brown Trout, Artic Char
and Atlantic Salmon, in addition to the 178-bp band discussed above we found a 400-bp
ampilcon associated with the lack of the 201-bp band. This raises the interesting
possibility that there is an alteration in the 3’ UTR of the UCP3 in these salmonid
species. Although significantly beyond the scope of the present study, we could
investigate the potential that this change may result in a significant alteration in metabolic
efficiency when comparing these different salmonid species, assuming that this alteration
leads to the change in the functionality of the UCP3 protein.
In the current study, we set out to identify the SINE elements found in the
transcribed regions of the gene. However, this shortly lead into the identification of the
UCP3 cDNA in the Rainbow Trout, and two splice variants. Based on the tissue
distribution, we project this protein to have a role in the base maintenance of a core body
temperature to allow normal function. Variation in the sequence and copy number of the
AvaIII SINE in the salmonid species has allowed their use as a maker of genetic
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varaiaton. Therefore, the relationship between this potential metabolic regulator and the
phylogenetic marker may prove useful as a genetic marker of body partitioning or other
marketable traits.
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1
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Figure 1- Determination of Amplicon size from the PCR screening of liver cDNA library
with the AvaIII #6 Primer (see materials and methods) and either T3 (lane 1) or T7
(lane 2) promoter primer. Products separated on 1% agarose gel and stained with
Ethidium Bromide.

Table 1- Expressed Sequences identified by PCR screening of liver cDNA library as
containing the AvaIII SINE element, and length of the SINE element found in each
transcript
Clone ID
RTI#12
Ava#6
Ava#34

Gene Identity
28s Ribosomal RNA
Uncoupling protein 3
Unknown

SINE Location
3’-UTR
3’-UTR
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SINE Length
25 bp
121 bp
231 bp

ggctccctgggactgtagtttgggctctcacgtcctgcagtaaaccaatagctagtcaaacggattttaatccacaggat
taataacaattaccagggaccATGGTGGGAATGAAGCCCTCCGATACACCCCCTACCCTGGGGGTGAAGCTGCTGAGT
M V G M K P S D T P P T L G V K L L S
GCTGGCTCAGCGGCCTGCATCGCTGACCTGGTCACCTTTCCCCTGGATACAGCCAAAGTCAGACTCCAGGTAATGGTTC
A G S A A C I A D L V T F P L D T A K V R L Q
ACTGTCCACCTCCAGCCCTGAAGACTTGAGTCTGACCTCCTGTAACTCTGAATTTTACTGGCACCTCCTGTAACACTGAT
TCTTGTGGGGACCTCCGTTAACACTGACACTTGTGAACCCCAGATTCAGGGAGAGAAGGTGGCGTCGGAAGCTACCAA
I Q G E K V A S E A T K
GGGCATCCGCTACAGGGGGGTGTTTGGGACAATCAAGTACCATGATCCGGACGGAGGGGCCAGGTCGCTTGATAACGGT
G I R Y R G V F G T I K Y H D P D G G A R S L D N G
CTGGTGGCGGGCTTACAGAGACAGATGTGCTTTGCCTCCATCAGGATCGGCTTCTATGACAACGTCAAAAACTTCTACT
L V A G L Q R Q M C F A S I R I G F Y D N V K N F Y
CTGGCGGCGCAGACAGTAAATTAGGATAACAGTTATTCATCGGAGATAATAATCTGTGATGTTACATATTTTGTACCAA
S G G A D
GAGAAGAAGCATCATATAGTACCTCAATCATCATCCTTTCAGTACTTAACAAACCCTCTGCCCCTGTCCTATCCCAGCT
T
GCAAATATTGGTATCCGTATCTTGGCCGGCTGCACCACAGGGGCCATGGCTGTGTCTTTCGCCCAGCCCACGGACGTGG
A N I G I R I L A G C T T G A M A V S F A Q P T D V
TGAAGGTCCGCTTCCAGGCTCAGGTCAACCTGACCGGGGTGGCTCGTCGCTACACGGGCACCATGCAGGCCTACAAACA
V K V R F Q A Q V N L T G V A R R Y T G T M Q A Y K H
CATTTTCAACCACGAGGGCATCCGCGGGCTCTGGAAAGGTTAGTTAGTACAACCCTGGGCCCATCGGTTAATTGCAGGT
I F N H E G I R G L W K
ACACCAATCTCCATTGGTTGTGTTGCTGCTAGCTTTGAGCCCCATTGATTGTGTTTGTCCGTAGTGGAACTGTTTGCATA
GAAAAGACCAAAGATTGTTGTCTATGTCACTGTCATTCAATGTCAGGGATGTACAGATATTGATTGGAGCAGATACTGCA
AAGTTGATGATCCCATAGGACAGAACTTGAGTGCACCTGAAAATAAAGCTTAGCTTTGCAGGTTGTTGTTGAGTTTTCTT
GGGCCTTTTACTAATGATAGACTAGTGGTTTAATTCTGGTATAACTATTGGGGTTATCAACCAACCGACGTGCTTCTTGT
TCACTCCAGGCTGTCTACCCAACATCACTAGGAACGCTCTGGTCAACTGCACAGAGCTTGTGACCTATGACCTCA
G C L P N I T R N A L V N C T E L V T Y D L
TCAAGGAGGCCATTCTTAGGCACAACCTGTTGTCAGATAACCTCCCGTGTCATTTTGCTTCTGCGTTCGGCGCCGGCTT
I K E A I L R H N L L S D N L P C H F A S A F G A G F
CGTTACCACCTGCATTGCCTCTCCGGTGGACGTGGTGAAGACACGATACATGAACTCTCCGCCGGGCCAGTATAAGAGT
V T T C I A S P V D V V K T R Y M N S P P G Q Y K S
GCCATCAACTGTGCCTGGACCATGGCCACCAAAGAGGGACCCACGGCCTTCTACAAAGGATTTGTGCCCTCATTTCTAA
A I N C A W T M A T K E G P T A F Y K G F V P S F L
GGCTGGGCTCATGGAACGTTGTGATGTTTGTGTCGTTTGAGCAGCTCAAGAGAGTCATGATGGTAGGAAAGCAGAAGAT
R L G S W N V V M F V S F E Q L K R V M M V G K Q K M
GGAGGACAAAAGTTAActtcattcctatgtgcaaagagccctttgcaatgatgacaagcgcacaaaccctagccatatt
E D K S
gagttggacccacaatgtagtgtagactacaggaacactatggaccacgattcataacgttaagattcctatgtgttcga
ctgtcagcatgttgtatgaataatgaggaatcctttgttaaaaaaggagttgtgaaagtgcatttgaagtgcatctacct
tggagaacagttttattttctctattatttattttgacctatacttctcctacggtctcaaaccagtccatggggacctc
tagccattctctatagtgtatttagcacacctgccaaatgtgaactaatcagcaagctgctgttactttaaatcagatgt
actagggttaggatacagagtactctaggaacgactagagttaaggcagccccctccgcaacgctctgatttagaggggt
tgggttaaatgcggaggacacatttcagttgaacgcattcagttgtgcaactgactaggtctccccctttctcttaattc
cccccccaaaacttttaattagttatagtttaataattagtatttagatggaggtaatttgcaatatattgaacttaata
aatatactttgtttgtaaaaaaaaaaaaaaa

Figure 1 – cDNA sequence of Rainbow trout UCP3 with the translated 309 aa peptide
sequence. Additionally, this figure shows the insertions included in UCP3v1
(Underlined and Underlined Italic Sequence) and UCP3v2 (Underlined Italic
Sequence) and the location of the AvaIII SINE (Italic Sequence).
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Figure 2 – UCP3 gene expression pattern in tissues from rainbow trout. This shows both
the electrophoresis of PCR Products (A) and the Southern Blot analysis (B). UCP3
(830 bp) and UCP3v2 (971 bp) were the only transcripts detected in the tissues, with
highest expression of UCP3 in the liver and the heart. UCP3v1 (1473 bp) transcript
was not detected in the tissues screened. Tissues screened: B-Brain, H-Heart, LLiver, K-Kidney, M-Skeletal Muscle, P-Pituitary, St-Stomach, I-Intestines, E-Eye,
Sk-Skin, Ft-Fat Tissue, Co-Control Plasmid.
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Figure 3 – Conservation of the AvaIII SINE element in the 3’ UTR of the UCP3
transcripts among Rainbow Trout strains and other Salmonid Species as determined
by Gel Electrophoresis of PCR Products (A) and Southern Blot Analysis (B). In
addition to the expected 201 bp band, a 178 bp product common to all of the samples
screened, and a 400 bp band was identified in a few samples. Samples: Lanes 1-6 –
Rainbow Trout Kamloop, Lane 7 – Rainbow Trout Red Band, Lanes 8-9 – Rainbow
Trout Cutthroat, Lane 10 – Rainbow Trout Steelhead, Lanes 11-12 – Brook Trout,
Lanes 13-14 – Brown Trout, Lanes 15-16 – Artic Char, Lanes 17-20 – Atlantic
Salmon, Lanes 21-24 – Pacific Salmon.
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Appendix 3
Activin-B, Activin Type-I and –II Receptors, and Follistatin Gene
Expression in MCF-7 and MDA-MB-231 Breast Tumor Cell Lines
ABSTRACT
Background: Activins are members of the transforming growth factor beta (TGF-β)
family and are known to modulate the proliferation and differentiation of several cell
lines. Follistatins, monomeric glycosylated proteins, specifically neutralize the biological
actions of activins as well as other members of the TGF-β family. The objective of the
present study was to investigate the relationship between TGF-β sensitivity and gene
expression of activin-B, activin receptor type-I and -II, follistatin and myostatin in the
TGF-β-sensitive (MDA-MB-231) and -resistant (MCF-7) breast cancer cell lines.
Materials and Methods: Cell cultures were maintained in 7% CO2 in DMEM + 10%
FBS and gentamicin. Reverse transcription polymerase chain reaction (RT-PCR) was
used to determine the expression profile of the aforementioned genes.
Results: Activin-B, receptor type–I, and follistatin gene expression were higher in the
MDA-MB-231 than in MCF-7 cell line, whereas receptor type-II expression was similar
in both cultures. We also examined the gene expression level of myostatin, a recently
identified TGF-β family member, and myostatin mRNA was not identified in either cell
line.
Conclusion: The expression profile of activins, their receptors and binding protein
(follistatin) indicate a potential relationship between the TGF-β sensitivity and expression
of these genes in the investigated cell lines.
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Keywords: Activin, Activin Receptors, Follistatin, MCF-7 Cells, MDA-MB-231 Cells
Abbrevations: TGF-β = Transforming Growth Factor-β, RT-PCR = Reverse
Transcription-Polymerase Chain Reaction, ER = Estrogen Receptor

INTRODUCTION

Activins, members of the Transforming Growth Factor-β (TGF-β) family, exist as
three distinct β subunits (βA, βB, βC) in humans. However, only βA and βB subunits
have been shown to form biologically active dimers (βAβA, βBβB and βAβB) [1].
Activins function through TGF-β family receptors (activin receptors), type-I and type-II
[2]. Activins bind to the type-II receptor forming a complex, which then recruits the
type-I receptor to initiate the serine/threonine kinase signal transduction pathway [1].
Follistatins, functioning as activin binding proteins, are glycosylated monomers resulting
from alternate splicing (288 and 315 aa forms) and proteolytic modification (300 aa
form) of a single gene transcript [3]. Follistatins bind to the β-subunits of the activin
molecules and thereby attenuate their activity [1]. Both activins and follistatins have
been found in a number of tissues and are thought to interact in an autocrine/paracrine
fashion during development [4].
Altered activin/follistatin gene and protein expression have been reported in ovarian
epithelial carcinomas [5], human pituitary adenoma [6], and prostastic cancer cell lines
[7], indicating a potential role for the activin/follistatin system in development or
progression of cancer. However, the effect of activins on tumor cell growth seems to
diverge among different cell types.

For example, activins are mitogenic for

embryocarcinoma P19 cells, while inhibiting profileration for the Y-79 rentinoblastoma
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cells [1]. The role of activins, their receptor and follistatin in the regulation of breast
cancer development is possibly limited by the sensitivity of the cells. The MDA-MB-231
(estrogen receptor (ER) negative) cells have been shown to be more sensitive to TGF-β
family members than the MCF-7 (ER-positive) cell line [8,9,10].

Additionally, the

effects of estrogens [10] and progestins [11] on breast cancer cell lines were positively
correlated to reduced TGF-β family expression.
Myostatin, a novel member of the TGF-β family, has been proposed as a negative
regulator of muscle cell proliferation [12] and could play a role in the regulation of tumor
cells. Additionally, Ji et al., [13] found significant myostatin expression in the lactating
mammary glands of pigs.

Therefore, a potential relationship between myostatin and

breast tumor development may be postulated.
Members of the TGF-β family have been shown to inhibit proliferation of breast
cancer cell lines [10]. Therefore, profiles of endogenous TGF-β family gene expression
may provide a better understanding of and development of better breast cancer
treatments.

In the current study, we investigated the relationship between TGF-β

sensitivity and the gene expression profiles of activin-B, activin receptor type-I and typeII, follistatin and myostatin in MCF-7 and MDA-MB-231 breast tumor cells.

MATERIALS and METHODS
Cell Culture
Permanent cell lines derived from a human breast carcinoma were used in the
current study. MCF-7, between passage numbers 40 and 50 and MDA-MB-231, between
passage numbers 15 and 60, were maintained in Dulbecco’s Modified Eagle’s Medium
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(DMEM) (Bio Whittaker, Rockland, ME) supplemented with 10% fetal bovine serum
(FBS), and 40 µg/ml gentamicin. The cells were maintained at 37°C in a humidified
atmosphere of 93% air and 7% CO2. As the cells approached confluence, they were
passaged weekly at a 1:5 ratio (MCF-7) and 1:10 ratio (MDA-MB-231).

RT-PCR
RNA isolation and RT-PCR were performed as previously outlined [14]. Briefly,
50 µL of the PCR cocktail containing: 5 µL of 10x Taq buffer (1.5 mM MgCl2 final
concentration), 1 µL dNTPs (final concentration 0.2 mM each), 1 µL of sense and antisense primers (1 mM final concentation), 1 µL of Taq DNA Polymerase (Display
Systems Biotech, Vista, CA) and 41 µL of nuclease free water to 2 µL of the reverse
transcription reaction. The PCR started with one cycle consisting of denaturing (94°C)
for 5 min, annealing (65°C for activin-B, 60°C for activin type-II receptor, 55°C for βActin) for 1 min, and extension (72°C) for 1½ min. The first cycle was followed by 30
cycles consisting of 1 min intervals of denaturing at 94°C followed by annealing at (65°C
activin-B, 60°C for activin type-II receptor, 55°C for β-actin followed by extension at
72°C.

These cycles were followed by a final 10 min extension step (72°C).

For

follistatin and activin type-I receptor, touchdown PCR was run. This program consisted
of a 5-min denaturation step (94°C), followed by 5 cycles in which the initial annealing
temperature of 72°C was reduced by 1°C per cycle, then 30 cycles in which the annealing
temperature was 68°C. Again the reaction was concluded with a 10 min extension step at
72°C. Gene specific primers (Table 1) were designed based on published sequences for
each gene, and obtained from Gibco BRL Inc. (Grand Island, NY). All reactions were
run on a PTC-200 thermocycler (MJ Research, Watertown, MA). A water control (no
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cDNA) reaction was run with each cocktail to assure there was no contamination of the
components of the reactions. The identity of the PCR products was verified by sequence
analysis.
The amplified gene products were visualized by electrophoresis on 1.5% agarose
gels stained with ethidium bromide (0.2 mg/mL). The gene products were photographed
under UV light using FluorChemTM Imaging System (Alpha-Innotech Corp., San
Leandro, CA) and quantified by densometric analysis of the photograph using
FlourChemTM Software (Alpha-Innotech Corp., San Leandro, CA). The densitometric
values for each gene product were normalized to densitometric values of the β-Actin
housekeeping gene.

Statistical Analysis
Analysis of Variance was performed using the GLM procedure of SAS® (SAS
Institute, Cary, NC). Means for each gene were compared between the two cell lines.
For all analyses, statements of significance were based on P<0.05 unless otherwise noted.

RESULTS
β-Actin expression levels did not differ between the two cell lines (data not
shown) and therefore was deemed suitable for normalization of the densitometeric values.
As shown in figure 1, activin-B expression was observed in both the MCF-7 and MDAMB-213 cells lines, and the level was higher in the MDA-MB-231 cells than in the MCF7 cells (P<0.01). In both the MDA-MB-231 (ER -) and MCF-7 (ER +) cell lines, similar
expression of the activin type-II receptor was found (figure 2). However, we found
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higher expression of the activin type-I receptor in the MDA-MB-231 cell line (figure 3,
P<0.03). Follistatin expression was determined to be higher in the MDA-MB-231 cells
as compared to the MCF-7 cells (P<0.03, figure 4). We were unable to detect any
myostatin expression in either cell line (data not shown).

DISSCUSSION
Jeng et al. [10] demonstrated a difference regarding TGF-β family member
sensitivity among different breast tumor cell lines. Specifically, they indicated that the
MDA-MB-231 cells were less sensitive to inhibition of proliferation by TGF-β members
than the MCF-7 cells. This difference could be attributed to receptor limitations in the
cell lines, i.e. gene mutations or reduced expression [9]. Liu et al [15] showed that both
ER+ (MCF-7) and ER- (MDA-MB-231) cell lines expressed the activin type-II receptor
as reflected in the current study. We showed a significant reduction in the expression of
the activin receptor type-I in MCF-7 cells. Suggesting that MCF-7 cells may be less
sensitive to activin treatment than MDA-MB-231 cells. However, it has been found that
activin-A reduced proliferation and altered colony morphology of the MCF-7 cells [15].
With respect to the MCF-7 cell line, it was determined that higher passage numbers
reduced TGF-β sensitivity [10]. Thus, the incongruity between the previous reports
[10,15] and the current study may be related to the passage numbers of the cells studied.
The current experiment used a moderate passage number (40-50). Therefore, we should
not overlook the possibility that the loss of the activin receptor type-I expression may be
the result of the increased passage number.
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A number studies have shown the co-expression of activin-B and follistatin in a
variety of cell culture systems [for review see 1], consistent with the cell lines
investigated in the current study. Additionally, both in vitro and in vivo studies show that
exogenous activin treatment lead to increased follistatin expression [for review see 2].
We may therefore infer that the increased follistatin expression in the MDA-MB-231
cells may be the response to the higher levels of endogenous activin-B. Attenuation of
follistatin in the MCF-7 cells would be expected because these cells showed not only a
lower activin-B expression, but also lower receptor type-I expression. Collectively, these
data indicate that regulatory interactions between activins and follistatin appear to exist in
these breast tumor cell line.
CONCLUSION
The expression of activins, their receptors and one of their binding proteins
(follistatin) in both an ER (+) (MCF-7) and ER (-) (MDA-MB-231) breast cancer cells
lines was investigated. We conclude that the expression of activin-B, activin receptor
type-I and follistatin are different between the two cell lines. The expression profiles of
activins, their receptors and binding proteins (follistatins) indicate a potential explanation
for the differences in TGF-β sensitivity of the investigated cell lines. Thus, the role of
activins and follistatins in the development and progression of breast cancers should be
considered when evaluating novel treatments. Additionally, we showed that the
regulatory interactions between the activins and follitsatins appeared to be intact, and
therefore may be useful in evaluating both the type of cancer and prospective treatments.
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Appendix 4
IGF-I, IGF-II AND IGF-RECEPTOR-1 TRANSCRIPT AND IGF-II PROTEIN
EXPRESSION IN MYOSTATIN KNOCKOUT MICE TISSUES
(Published in Kocamis et al., 2002. Muscle and Nerve (in press))

ABSTRACT

Semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and
immunohistochemistry were performed to demonstrate whether a correlation exists
between insulin-like growth factors, positive regulators of growth, and myostatin, a
negative regulator of muscle growth. IGF-I, -II and IGF-receptor-1 mRNA (IGF-R1) and
IGF-II protein expressions were determined in control and myostatin knockout mice
tissues. IGF-I gene expressions were similar between control and knockout mice tissues,
whereas IGF-II mRNA levels were significantly higher in myostatin knockout mice
kidney and soleus muscles than those of control mice (P < 0.01). IGF-R1 mRNA levels
from control mice heart (P < 0.05) and kidney (P < 0.01) were significantly higher than in
myostatin knockout mice, whereas levels were lower in pectoralis muscle of control mice
than knockout mice (P < 0.01). The strongly IGF-II positive cells in soleus muscle were
more common in myostatin knockout mice and were seen in a few foci in control mice.
IGF-II immunoreactivity in both control and myostatin knockout mice kidneys was
localized to the epithelium of renal tubules and collecting ducts. Reciprocal changes in
the expression of myostatin and IGF-II and IGF-R1 may facilitate the better
understanding not only of skeletal muscle growth but also of other organ development in
mammalians, as well as of the pathophysiology of these tissues associated with disease.
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INTRODUCTION
Insulin-like growth factors (IGF-I and -II) are produced by several different
tissues and are essential for both embryonic and postnatal development.5,13 Severe
disruption of tissue development, particularly in skeletal muscles, was observed in IGF-I
or IGF-II knockout mice. For instance, IGF-I knockout mice were significantly smaller
than their control littermates and had reduced development of muscle tissue,18 whereas
transgenic mice overexpressing IGF-I showed enhanced body growth with an increase in
muscle mass.14 Additionally, IGF-II expression has been positively associated with
skeletal muscle development in double-muscled cattle 11 and in pig breeds with
exceptional muscle mass. 16 In vitro, both IGFs inhibited apoptosis 22 and promoted
proliferation and differentiation of skeletal muscle cells.1 As evidenced by these in vivo
and in vitro findings, IGFs are undoubtedly important components of skeletal muscle
development.
When the myostatin gene (also known as growth differentiation factor 8), a
recently identified member of the TGF-β family, was disrupted by homologous
recombination in mice, skeletal muscle mass significantly increased, up to three times the
normal size.15 Increased muscle mass in these mice was due predominantly to hyperplasia
but also involved hypertrophy. Additionally, myostatin mutation resulting in functional
loss of the protein has been linked to double-muscled cattle breeds.8,10 Therefore, it has
been proposed that myostatin is a negative regulator of skeletal muscle growth. We
postulated that the ratio of mRNA and protein levels between IGFs, positive regulators of
muscle growth, and myostatin, a negative regulator, may serve as indicators of skeletal
muscle mass. Also, based on the gene knockout observations, IGFs, in addition to being a
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pivotal regulator of muscle growth, appear to be involved in controlling overall growth,
whereas myostatin seems to be acting only on muscle growth. Thus, to demonstrate
whether a correlation exists between IGFs and myostatin, IGF-I, -II and IGF-receptor-1
mRNA (IGF-R1) and protein levels were determined in a wide variety of myostatin
knockout mice tissues.

MATERIALS and METHODS
Animals
Nine-month-old male myostatin knockout (n= 3, SVJ/129) and control mice (n=
3, C57Bl/6) were generously provided by Metamorphix Inc., (Baltimore, MD).
Euthanasia of mice and subsequent tissue collections were performed in compliance with
an approved West Virginia University Animal Care and Use Committee protocol.
RNA extraction and RT-PCR
Total RNA was extracted separately from myostatin knockout and control mouse
brain, heart, liver, kidney, and skeletal muscle tissues (soleus, gastrocnemius, and
pectoralis) using the Tri-Reagent (Sigma, St. Louis, MO) modification of the guanidine
isothiocyanate/phenol-chloroform method.4 The RNA concentration was estimated by
absorbance at 260 nm in a Shimadzu spectrophotometer (Model UV-1201, Columbia,
MD). The integrity of the RNA was assessed by UV visualization of ethidium-bromide
stained intact 28S and 18S bands on a mini-agarose gel. Samples of RNA were stored at 80 C.
Reverse transcription (RT) was performed by adding 2 µg of total RNA to 2 µg of
oligo dT primers and sterilized nuclease-free dd H2O in a final volume of 15 µl. The
samples were heated at 70o C for 5 minutes and then immediately cooled to 4o C for 2
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minutes. Reverse transcription buffer containing dNTPs (final concentration of each was
10 mM), 25 units of RNase inhibitor, and 200 units of murine maloney leukemia virus
reverse transcriptase (Promega, Madison, WI) were added to each sample. The sample,
with a final volume of 40 µl, was incubated at 37o C for 1 hr followed by a 5 min
incubation at 95o C. For the PCR reaction, 2 µl of RT reaction mixture were added to 50
µl of solution containing 5 µl of Taq buffer, 1 µl Taq DNA polymerase (Display Systems
Biotech, Vista, CA), 1 µl dNTPs (final concentration of each was 10 mM), 1 µl each of
forward and reverse primers, and 41 µl sterile nuclease-free dd H2O. The PCR reaction
started with one cycle consisting of 94o C for 5 minutes, an annealing step of 65o C for
IGF-I or 55o C for IGF-II and β-actin for 1 minute and extension at 72o C for 1 minute.
The first cycle was followed by 30 cycles (25 cycles for β-actin) consisting of 45-s
intervals of 94o C, followed by 65o C for IGF-I or 55o C for IGF-II and β-actin, followed
by 72o C. For IGF-RI, touchdown PCR was run. This program consisted of a 5-minute,
94o C denaturation step, followed by 5 cycles in which the initial annealing temperature
of 72o C was reduced by 1o C per cycle, then 30 cycles in which the annealing
temperature was 68o C. Denaturation, extension and annealing time were programmed as
described above. To establish a linear range of amplification for each gene, several
different cycle numbers of PCR (10, 15, 20, 25 and 30 cycles) were run. As a control, a
PCR reaction without c-DNA was run, and no contamination was found in the reaction
mixtures (data not shown).
PCR primers
All PCR primers were synthesized by Gibco BRL Inc. (Grand Island, NY).
Primers for IGF-I were designed on the basis of published sequences of chicken IGF-I.2
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The sequence of the forward primer was 5 GCTGAGCTGGTGGATGCTCTTCAGTTC
3, and the reverse primer was 5 CTTCTGAGTCTTGGGCATGTCAGTGTG 3. Forward
and reverse primers predicted a PCR product of 215 base pairs (bp), which corresponds
to bases (160-265) of the sequence. Primers for IGF-II were designed on the basis of
published sequences of chicken IGF-II.19 Primers for IGF-II amplified a PCR product of
356 bp which corresponded to bases (1041-1397) of the sequence. The sequence of the
forward primer for IGF-II was 5 GAGCTTGTTGACACGCTTCAGTTTGTC 3, and the
reverse primer was 5 ACGTTTGGCCTCTCTGAACTCTTTGAG 3. Primers for IGF-R1
were designed on the based of published sequence of mouse IGF-I.21 The sequence of the
forward primer was 5 GACATCCGCAACGACTATCAG 3, and the reverse primer was
5 GTAGTTATTGGACACCGCATC 3. Primers for IGF-R1 amplified a PCR product of
395 bp that corresponded to bases (114-509) of the sequence. Forward and reverse
primers for β-actin were predicted to amplify a 285 bp product as previously published,24
as an internal standard to verify the level of amplification. The sequence of the forward
primer was 5 TCATGAAGTGTGACGTTGACATCCGT 3, and the reverse primer was
5 CCTAGAAGCATTTGCGGTGCACGATG 3.
The amplified PCR products for each gene were visualized on 1.5 % agarose gels
stained with ethidium bromide. Products were analyzed by densitometry of stained gels,
and data should therefore be considered to be semiquantitative. The identity of all PCR
products was confirmed by sequence analysis.
Immunohistochemistry
Kidney and soleus muscles from adult myostatin knockout and control mice were
immersion fixed in Prefer fixative (Anatech, Battle Creek, MI). Sections were processed
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overnight and embedded in paraffin. Unstained sections were cut at 5 µm and incubated
at 60o C for 20 minutes. Sections were then deparaffinzed in 3 baths of xylene (6 minutes
each), a bath of 100% alcohol (3 minutes), a bath of 95% alcohol (3 minutes), a bath of
80% alcohol (3 minutes), and a final bath of distilled water for 5 minutes. The sections
were then placed in a coplin jar with 0.01M EDTA (pH 8, Fisher Scientific, Pittsburgh,
PA) for antigen retrieval. The coplin jar was placed in microwave on high for 1 minute,
45 seconds to bring temperature up to boiling point. A defrost cycle was set for 6
minutes that kept the solution just below boiling. After 6 minutes, the coplin jar was
removed from the microwave and allowed to sit for 20 minutes. The slides were then
rinsed and incubated in distilled water for 5 minutes. Slides were incubated in 3%
hydrogen peroxide for 10 minutes at room temperature. After rinsing with distilled
water, slides were incubated in Tissue Conditioner (Biomeda, Foster City, CA) for 10
minutes at 37o C. Slides were rinsed with distilled water and placed in TBS (Dako,
Carpinteria, CA) for 5 minutes. After diluting with antibody diluent (1/100; Dako,
Carpinteria, CA), IGF-II goat anti human antibody (Sigma, St. Louis, MO) was applied
as a drop on the section for 1 hour at room temperature. Slides were then rinsed with
distilled water and incubated in tris buffered saline (TBS) for 5 minutes at room
temperature. Vectastain biotinylated secondary antibody (anti goat IgG) was applied as
outlined by the manufacturer (Vectastain ABC kit, Vector Laboratories, Burlingame, CA)
for 30 minutes at room temperature. Slides were then rinsed with distilled water and
incubated in TBS for 5 minutes at room temperature. Vectastain ABC (avidinbiotinylated enzyme complex) reagent was applied for 30 minutes at room temperature.
Slides were rinsed with distilled water and incubated in for 5 minutes at room
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temperature. Aqueous hematoxylin (Biomeda, Foster City, CA) was applied as a drop on
over section for 2 minutes to counterstain. Then slides were rinsed in tap water and
coverslipped with Crystal Mount (Biomeda, Foster City, CA). After crystal mount was
dried, they were post-mounted with Permount (Fisher Scientific, Pittsburgh, PA) and a
glass coverslip was placed over the Permount.
Whole section digital images were captured using a Sprint Scan slide scanner
(Polaroid, Cambridge, MA) and a PathScan Enabler (Myer Instruments, Houston, TX).
Digital photomicrographs were captured using a Quantix digital camera (Photometrics,
Tucson, AZ). For digital capture, images from control and knockout mice were captured
in the same session using identical settings. Western blotting was used to validate the
quality of the primary antibody. Rabbit Super Sensitive Control Serum (Biogenex, San
Ramon, CA) in place of primary antibody was used as a negative control on one section
for each run.
Statistical Analysis
Probability of differences of least-square means was used to compare densitometric
values (General Linear Model procedure of SAS, SAS Institute Inc., Cary, NC).
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RESULTS
β -Actin, IGF-I, IGF-II and IGF-R1 mRNA Expression
β-Actin mRNA expression was not different for the same tissues between control
and myostatin knockout mice (Fig. 1). IGF-I gene expression for brain, heart, liver,
kidney and pectoralis muscles were similar between control and knockout mice, and no
IGF-I mRNA was detected in either control or knockout mice soleus muscles (Fig. 2).
IGF-II mRNA levels were significantly higher in kidney and soleus muscles of myostatin
knockout mice than control mice (P < 0.01, Fig. 3). No IGF-II gene expression was
observed in liver of control and myostatin knockout mice (Fig. 3). IGF-Receptor-1
mRNA levels from control mice heart (P < 0.05) and kidney (P < 0.01) were significantly
higher than from myostatin knockout mice, whereas levels were lower in pectoralis
muscle of control mice than knockout mice (P < 0.01, Fig. 4). IGF-R1 gene expression
was similar in brain, liver, soleus and gastrocnemius muscles of both control and
myostatin knockout mice.
IGF-II Immunohistochemistry
An IGF-II immunohistchemistry negative control is shown in Figure 5. IGF-II
was principally localized to small cells located adjacent to soleus muscle myofibers (Fig.
6). The strongly IGF-II positive cells were more common in myostatin knockout mice
and were seen in a few foci in control mice. The IGF-II positive cells are believed to be
satellite cells based on location and size. IGF-II immunoreactivity in both control and
myostatin knockout mice kidneys was localized to the epithelium of renal tubules and
collecting ducts (Fig. 7). No consistent differences in expression were noted between the
two groups of mice.
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DISCUSSION
Although both IGF-I and IGF–II are well-known positive regulators of muscle
growth, their gene expressions in the current study demonstrated different patterns
between muscle tissues of myostatin knockout and control mice. IGF-I mRNA levels
from soleus (predominantly red fibers), gastrocnemius (predominantly white fibers), and
pectoralis (white and red fibers) muscles were not different between myostatin knockout
and control mice (Fig. 2), but IGF-R1 mRNA levels from pectoralis muscles were
significantly higher in myostatin knockout mice than control mice (Fig. 4). By contrast,
IGF-II mRNA levels from soleus muscles were higher in mysotatin knockout mice than
control mice, and no difference was observed between myostatin knockout and control
mice gastrocnemius and pectoralis muscles (Fig. 3).
Based on the immunohistological findings of the present study, elevated IGF-II in
the soleus of myostatin knockout mice is believed to originate from activated satellite
cells. Varying expression patterns of IGF-I and IGF-II in myostatin knockout mice soleus
and gastrocnemius muscle could be explained as follows. First, because myostatin
mRNA and protein levels were higher in gastrocnemius than soleus muscle of normal
adult mice,3 complete absence of myostatin in the knockout mice may have triggered
distinct and novel muscle regulatory pathways in these two different fiber-type
dominated muscles, thereby causing the observed differences in the expression patterns
of IGF-I and –II. Second, Semsarian et al. (20) demonstrated that myostatin mRNA level
was not affected by IGF-I overexpression in C2C12 cell cultures. Along the same line,
the loss of skeletal muscle mass induced during space flight of rats was associated with
increased myostatin mRNA and protein levels in the skeletal muscle and decreased IGF-
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II mRNA, whereas no change in IGF-I mRNA level was observed.12 Based upon these in
vitro and in vivo findings, it is possible to expect that complete absence of myostatin
should increase IGF-II mRNA levels without effecting IGF-I levels. Indeed, our finding
of strong IGF-II mRNA and protein expression in soleus muscle of myostatin knockout
mice and no difference in IGF-I mRNA levels of soleus, gastrocnemius and pectoralis
muscle between these mice partially supports the in vitro and in vivo findings. Even
though no changes in either IGF-I or IGF-II levels from pectoralis muscles were observed
between myostatin knockout and control mice, IGF-R1 expression from the same muscle
was significantly increased in myostatin knockout mice (Fig. 4). Because both IGFs use
IGF-R1 for their mitogenic and myogenic signal transduction pathways,7 the significance
of increased IGF-R1 expression without corresponding increases of ligands from
pectoralis muscles of myostatin knockout mice remains to be further explored.
Additionally, the local or systemic production of the IGF binding proteins may play a
critical role in regulating the activity of these growth factors and therefore merits further
investigation.
In the present study, strong IGF-II gene expression was observed in myostatin
knockout mice kidney, whereas IGF-R1 expression was significantly lowered when
compared to control mice (Fig. 3 and 4, respectively). However, no consistent differences
in IGF-II immunoreactivity were observed between the two groups of mice. This was not
totally unexpected, as the enzymatic immunohistochemical techniques use amplification
cascades designed to maximize chromagen precipitation resulting from low levels of
antibody binding. Also, the similar distribution of IGF-II in control and knockout mice
(Fig. 7) suggests that changes in IGF-II expression result from increased expression in
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cells that normally express IGF-II rather than changes in the type of cells expressing IGFII. Body weight of transgenic mice overexpressing IGF-II was not different from control
mice but had increased kidney weight without any change in other organs.23 Although
myostatin knockout kidney weight was not measured in the current and previous
studies,15 increased IGF-II levels may have caused the decline in IGF-R1 mRNA
expression to maintain proper size of myostatin knockout mice kidney. Several studies,
however, have suggested that metabolic actions of IGF-II, unlike its mitogenic actions,
are not mediated through IGF-R1 but through insulin receptors, to which IGF-II can bind
with low affinity.6,9 Additionally, IGF-II, but neither insulin nor IGF-I, stimulated Na+-H+
exchange across the brush-border membrane of proximal tubular cells.17 Therefore, it is
possible that increased IGF-II levels from myostatin knockout mice kidneys may be due
to the disturbed metabolic balance in response to excess muscle growth of those mice.
Further studies regarding the measurements of both metabolic parameters, such as blood
glucose, fatty acids, and hormones such as insulin and growth hormone should be
conducted to clarify this speculation.
Because tissue samples were obtained only at one age, we do not know whether
the changes in IGF-I, IGF-II, and IGF-R1 gene and protein expression were the same
throughout the neonatal and adult life of the mice. Reciprocal changes in the expression
of myostatin and IGF-II and IGF-R1 may facilitate the better understanding of not only
skeletal muscle growth but also other organ development in mammalians as well as
pathophysiology of these tissues associated with disease.
Acronyms:
IGF – Insulin-like Growth Factor
IGF-R1 – Insulin-like Growth Factor-Receptor-1
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PCR – Polymerase Chain Reaction
RT – Reverse Transcription
TBS – Tris Buffered Saline
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Steady-state levels of β-actin mRNA in brain (B), heart (H), liver (L), kidney (K), soleus (S),
gastrocnemius (G), and pectoralis (P) muscle of control (n= 3) and myostatin knockout mice
(n= 3) tissues. The bands for β-actin were analyzed by densitometry and the integration
values (mean ± SD) were expressed in arbitrary units for each tissue.
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Figure 2. Steady-state levels of IGF-I mRNA in brain (B), heart (H), liver (L), kidney
(K), soleus (S), gastrocnemius (G), and pectoralis (P) muscle of control (n= 3) and
myostatin knockout mice (n= 3) tissues. The bands for IGF-I were analyzed by
densitometry and the integration values (mean ± SD), after normalization to β actin,
were expressed in arbitrary units for each tissue.
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Figure 3. Steady-state levels of IGF-II mRNA in brain (B), heart (H), liver (L), kidney
(K), soleus (S), gastrocnemius (G), and pectoralis (P) muscle of control (n= 3) and
myostatin knockout mice (n= 3) tissues. The bands for IGF-II were analyzed by
densitometry and the integration values (mean ± SD), after normalization to β actin,
were expressed in arbitrary units for each tissue. Means with asterisks were
significantly different (* P < 0.05,** P < 0.01).
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Figure 4. Steady-state levels of IGF-R1 mRNA in brain (B), heart (H), liver (L), kidney
(K), soleus (S), gastrocnemius (G), and pectoralis (P) muscle of control (n= 3) and
myostatin knockout mice (n= 3) tissues. The bands for IGF-R1 were analyzed by
densitometry and the integration values (mean ± SD), after normalization to β actin,
were expressed in arbitrary units for each tissue. Means with asterisks were
significantly different (* P < 0.05, ** P < 0.01).
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Figure 5. Rabbit Super Sensitive Control Serum (Biogenex, San Ramon, CA) in place of
primary antibody was used as a negative control on one section for each run. Note the
absence of red staining. Bar = 50 micrometers.
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Figure 6. IGF-II immunohistochemistry in control and myostatin knockout mice soleus
muscles. IGF-II immunoreactivity (red staining) was principally localized satellite
cells. Bar = 50 micrometers.
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Figure 7. IGF-II immunohistochemistry in control (A) and myostatin knockout mice (B)
kidneys. IGF-II immunoreactivity (red staining) was localized to the epithelium of
renal tubules and collecting ducts. Bar = 50 micrometers.
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